WO2007081720A2 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer - Google Patents
Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer Download PDFInfo
- Publication number
- WO2007081720A2 WO2007081720A2 PCT/US2007/000103 US2007000103W WO2007081720A2 WO 2007081720 A2 WO2007081720 A2 WO 2007081720A2 US 2007000103 W US2007000103 W US 2007000103W WO 2007081720 A2 WO2007081720 A2 WO 2007081720A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- gene product
- lung cancer
- expression
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- lung cancer is the primary cause of cancer death among both men and women. In 2002, the death rate from lung cancer was an estimated 134,900 deaths. Lung cancer is also the leading cause of cancer death in all European countries, and numbers of lung cancer-related deaths are rapidly increasing in developing countries as well.
- MicroRNAs are a class of small, non-coding RNAs that control gene expression by hybridizing to and triggering either translational repression or, less frequently, degradation of a messenger RNA (rnRNA) target.
- rnRNA messenger RNA
- the discovery and study of miRNAs has revealed miRNA-mediated gene regulatory mechanisms that play important roles in organismal development and various cellular processes, such as cell differentiation, cell growth and cell death (Cheng, A.M., et al., Nucleic Acids Res. 33: 1290-1297 (2005)).
- Recent studies suggest that aberrant expression of particular miRNAs may be involved in human diseases, such as neurological disorders (Ishizuka, A., et al., Genes Dev. 76:2497-2508 (2002)) and cancer.
- miR-16-1 and/or miR-15a has been found in human chronic lymphocytic leukemias (Calin, G.A., et al., Proc. Natl. Acad. Sci. U.S.A. PP:15524-15529 (2002)).
- the development and use of microarrays containing all known human microRNAs has permitted a simultaneous analysis of the expression of every miRNA in a sample (Liu, C.G., et al., Proc Natl. Acad. ScL U.S.A. 101:9740-9744 (2004)).
- microRNA microarrays have not only been used to confirm that miR-16-1 is deregulated in human CLL cells, but also to generate miRNA expression signatures that are associated with well-defined clinicopathological features of human CLL (Calin, G.A., et al., Proc. Natl. Acad. ScL U.S.A. 101:1175-11760 (2004)).
- the present invention is based, in part, on the identification of specific miRNAs associated with altered expression levels in lung cancer cells.
- the invention encompasses methods of diagnosing whether a subject has, or is at risk for developing, lung cancer.
- the level of at least one miR gene product in a test sample from the subject is compared to the level of a corresponding miR gene product in a control sample.
- An alteration e.g., an increase, a decrease
- the at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR-205, miR-192-prec, miR-224, miR-126, miR-24-2, miR-30a-5p, miR-212, miR-140, miR-9, miR-214, miR-17-3p, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216- prec, miR-219-1, miR- 106a, miR- 197, miR- 192, miR- 125a-prec, miR-26a- 1 -prec, miR- 146, miR-203, miR-199b-prec, let-7a-2-prec, miR-27b, miR-32, miR-29b-2, miR-220, miR-33, miR-181c-
- the at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR-155, miR-210, miR-126* and miR-224. In another embodiment, the at least one miR gene product is selected from the group consisting of miR-21, miR-205 and miR-216.
- the lung cancer is a lung adenocarcinoma and the at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR-155, miR-210, miR-126*, miR-126, miR-24-2, miR-219-1, miR-95, miR-192-prec, miR-220, miR-216-prec, miR-204-prec, miR-188, miR-198, miR-145 and miR-224.
- the level of the at least one miR gene product can be measured using a variety of techniques that are well known to those of skill in the art (e.g., quantitative or semiquantitative RT-PCR, Northern blot analysis, solution hybridization detection).
- the level of at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to one or more miRNA-specific probe oligonucleotides (e.g., a microarray that comprises miRNA-specific probe oligonucleotides) to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample.
- miRNA-specific probe oligonucleotides e.g., a microarray that comprises miRNA-specific probe oligonucleotides
- the microarray comprises miRNA-specific probe oligonucleotides for a substantial portion of all known human miRNAs.
- the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR- 205, miR-192-prec, miR-224, miR-126, miR-24-2, miR-30a-5p, miR-212, miR-140, miR-9, miR-214, miR-17-3p, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216-prec, miR-219-1, miR-106a, miR-197, miR-192, miR-125a-prec, miR-26a-l- prec, miR-146, miR-203, miR-199b-prec, let-7a-2-prec, miR-27b, miR-32, miR-29b-2, miR-220
- the invention also provides methods of determining the prognosis of a subject with lung cancer, comprising measuring the level of at least one miR gene product, which is associated with an adverse prognosis in lung cancer, in a test sample from the subject. According to these methods, an alteration in the level of a miR gene product that is associated with an adverse prognosis, in the test sample, as compared to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.
- the at least one miR gene product is selected from the group consisting of miR-155, miR-17-3p, miR-106a, miR-93, let-7a-2, miR-145, let-7b, miR-20 and miR-21.
- the lung cancer is a lung adenocarcinoma and the at least one miR gene product is selected from the group consisting of miR-155 and let-7a-2.
- the level of the at least one miR gene product can be measured as described herein (e.g., quantitative or semi-quantitative RT-PCR, Northern blot analysis, solution hybridization detection, microarray analysis).
- An alteration in the signal of at least one miRNA in the test sample, relative to the control sample is indicative of the subject either having, or being at risk for developing, a lung cancer with an adverse prognosis.
- an alteration in the signal of miR- 125a, miR- 125b- 1, miR- 224 and/or miR-21 is indicative of the subject either having, or being at risk for developing, a lung cancer with an adverse prognosis.
- an alteration in the signal of miR-155 and/or let-7a-2 in a sample from a subject with lung adenocarcinoma is indicative of an adverse prognosis.
- the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR-21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR-205, miR-192-prec, miR-224, miR-126, miR-24-2, miR-30a- 5p, miR-212, miR-140, miR-9, miR-214, miR-17-3p, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216-prec, miR-219-1, miR-106a, miR-197, miR-192, miR- 125a-prec, miR-26a-l-pre
- the invention also encompasses methods of treating lung cancer in a subject, wherein at least one miR gene product is deregulated (e.g., down-regulated, up- regulated) in the cancer cells of the subject.
- at least one isolated miR gene product is down-regulated in the lung cancer cells
- the method comprises administering an effective amount of an isolated miR gene product, or an isolated variant or biologically-active fragment thereof, such that proliferation of cancer cells in the subject is inhibited.
- the method comprises administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of lung cancer cells is inhibited.
- the methods of treating lung cancer in a subject additionally comprise the step of first determining the amount of at least one miR gene product in lung cancer cells from the subject, and comparing that level of the miR gene product to the level of a corresponding miR gene product in control cells. If expression of the miR gene product is deregulated (e.g., down-regulated, up-regulated) in lung cancer cells, the methods further comprise altering the amount of the at least one miR gene product expressed in the lung cancer cells. In one embodiment, the amount of the miR gene product expressed in the cancer cells is less than the amount of the miR gene product expressed in control cells, and an effective amount of the miR gene product, or an isolated variant or biologically-active fragment thereof, is administered to the subject.
- the amount of the miR gene product expressed in the cancer cells is greater than the amount of the miR gene product expressed in control cells, and an effective amount of at least one compound for inhibiting expression of the at least one miR gene is administered to the subject.
- the invention further provides pharmaceutical compositions for treating lung cancer.
- the pharmaceutical compositions comprise at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, and a pharmaceutically-acceptable carrier.
- the at least one miR gene product corresponds to a miR gene product that has a decreased level of expression in lung cancer cells relative to suitable control cells.
- the isolated miR gene product is selected from the group consisting of miR-126*, miR-143, miR-192, miR-224, miR-126, miR-30a-5p, miR-140, miR-9, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216, miR-219-1, miR-125a, miR-26a-l, miR-199b, let-7a-2, miR-27b, miR-32, miR-29b-2, miR-220, miR-33, miR- 181c, miR- 101-1, miR- 124a-3 , let-7f- 1 and a combination thereof.
- the pharmaceutical compositions of the invention comprise at least one miR expression-inhibition compound.
- the at least one miR expression-inhibition compound is specific for a miR gene product whose expression is greater in lung cancer cells than control cells.
- the miR expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-21, miR-191, miR- 210, miR-155, miR-205, miR-24-2, miR-212, miR-214, miR-17-3p, miR-106a, miR- 197, miR-192, miR-146, miR-203, miR-150 and a combination thereof.
- the invention also encompasses methods of identifying an anti-lung cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product in the cell.
- the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in lung cancer cells. An increase in the level of the miR gene product in the cell, relative to a suitable control cell, is indicative of the test agent being an anti-lung cancer agent.
- the at least one miR gene product associated with decreased expression levels in lung cancer cells is selected from the group consisting of miR-126*, miR-143, miR-192, miR-224, miR- 126, miR-30a-5 ⁇ , miR-140, miR-9, miR-124a-l, miR-218-2, miR-95, miR-145, miR- 198, miR-216, miR-219-1, m ⁇ R-125a, miR-26a-l, miR-199b, let-7a-2, miR-27b, miR- 32, miR-29b-2, miR-220, miR-33, miR-181c, miR-101-1, miR-124a-3, let-7f-l and a combination thereof.
- the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in lung cancer cells.
- the at least one miR gene product associated with increased expression levels in lung cancer cells is selected from the group consisting of miR-21, miR-191, miR-210, miR-155, miR-205, miR-24-2, miR-212, miR-214, miR-17-3p, miR-106a, miR-197, miR-192, miR-146, miR-203, miR-150 and a combination thereof.
- FIG. 1 shows graphs depicting the relative expression level of human miR-21 precursor (hsa-mir-21; top panels), human miR-126* precursor (hsa-mir-126*; middle panels) and human miR-205 precursor (hsa-mir-205; bottom panels) in lung cancer (Ca) and noncancerous (N) tissues, as determined by real-time RT-PCR analysis.
- Cancer samples were either adenocarcinoma or squamous cell carcinoma (SCC).
- SCC squamous cell carcinoma
- FIG. 2 depicts the expression of mature miRNAs for miR-21 (hsa-mir-21), miR-126* (hsa-mir-126*) and miR-205 (hsa-mir-205) in lung cancer samples (i.e., adenocarcinomas (Adeno) and squamous cell carcinomas (SCC)), as detected by solution hybridization.
- Ca represents cancerous lung tissues and N represents noncancerous lung tissues.
- 5S rRNA served as a loading control.
- FIG. 3 A is a dendrogram depicting a hierarchical clustering based on microRNA expression profiles of 13 lung cancer cell lines representing small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC).
- SCLC small cell lung carcinomas
- NSCLC non-small cell lung carcinomas
- FIG. 3B depicts a miRNA expression cluster view for 13 lung cancer cell lines (top), corresponding to those listed in FIG. 3 A.
- the expression levels of various miRNAs, listed at the right of the figure, are indicated according to color. Blue indicates expression levels below the median, black indicates expression levels that are about equal to the median, and orange indicates expression levels that are greater than the median. Gray indicates missing data points.
- FIG. 4 is a Kaplan-Meier survival curve for adenocarcinoma patients.
- Adenocarcinoma cases in which hybridization intensity was different from background were classified according to hsa-mir-155 expression, and the survival data were compared using the log-rank test.
- FIG. 5 is a Kaplan-Meier survival curve for adenocarcinoma patients.
- Adenocarcinoma cases in which hybridization intensity was different from background were classified according to hsa-let-7a-2 expression, and the survival data were compared using the log-rank test.
- FIG. 7 is a Kaplan-Meier survival curve for adenocarcinoma patients. Thirty two adenocarcinoma cases from an original cohort were classified according to precursor hsa-let-7a-2 expression, and the survival data were compared using the log- rank test.
- FIG. 10 is a Kaplan-Meier survival curve for adenocarcinoma patients. Sixty four adenocarcinoma cases from a combination of 2 independent cohorts were classified according to precursor hsa-mir-155 expression, as estimated by real-time RT-PCR analysis. The survival data were compared using the log-rank test.
- FIG. 11 is a Kaplan-Meier survival curve for adenocarcinoma patients. Sixty four adenocarcinoma cases from a combination of 2 independent cohorts were classified according to precursor hsa-let-7a-2 expression, as estimated by real-time RT-PCR analysis. The survival data were compared using the log-rank test.
- FIG. 12 depicts the expression of MYOl 8B mRNA after treatment with 5-aza- dC and/or TSA in two lung cancer cell lines (Hl 57, A549), as determined by RT-PCR analysis.
- Lane 1 no treatment; lane 2, treatment with 1.0 ⁇ M 5-aza-dC for 72 hr; lane 3, treatment with 1.0 ⁇ M TSA for 24 hr; lane 4, treatment with 1.0 ⁇ M 5-aza-dC for 72 hours, followed by treatment with 1.0 ⁇ M TSA for 24 hr.
- GAPDH expression served as a loading control.
- microRNA gene product a "miR gene product,” "microRNA,” “miR,” or
- miRNA refers to the unprocessed or processed RNA transcript from a miR gene. As the miR gene products are not translated into protein, the term “miR gene products” does not include proteins.
- the unprocessed miR gene transcript is also called a "rniR precursor," and typically comprises an RNA transcript of about 70-100 nucleotides in length.
- the miR precursor can be processed by digestion with an RNAse (for example, Dicer, Argonaut, RNAse III (e.g., E. coli RNAse III)) into an active 19-25 nucleotide RNA molecule. This active 19-25 nucleotide RNA molecule is also called the "processed" miR gene transcript or "mature" miRNA.
- the active 19-25 nucleotide RNA molecule can be obtained from the miR precursor through natural processing routes (e.g. , using intact cells or cell lysates) or by synthetic processing routes (e.g., using isolated processing enzymes, such as isolated Dicer, Argonaut, or RNAse III). It is understood that the active 19-25 nucleotide RNA molecule can also be produced directly by biological or chemical synthesis, without having to be processed from the miR precursor. When a microRNA is referred to herein by name, the name corresponds to both the precursor and mature forms, unless otherwise indicated.
- the present invention encompasses methods of diagnosing whether a subject has, or is at risk for developing, lung cancer, comprising measuring the level of at least one miR gene product in a test sample from the subject and comparing the level of the miR gene product in the test sample to the level of a corresponding miR gene product in a control sample.
- a "subject" can be any mammal that has, or is suspected of having, lung cancer.
- the subject is a human who has, or is suspected of having, lung cancer.
- the lung cancer can be any form of lung cancer, for example, lung cancers of differing histology (e.g., adenocarcinoma, squamous cell carcinoma). Furthermore, the lung cancer may be associated with a particular prognosis (e.g., low survival rate, fast progression).
- a particular prognosis e.g., low survival rate, fast progression.
- Tables Ia and Ib depict the nucleotide sequences of particular precursor and mature human microRNAs.
- Table Ia- Human microRNA Precursor Sequences
- An underlined sequence within a precursor sequence corresponds to a mature processed miR transcript (see Table Ib). Some precursor sequences have two underlined sequences denoting two different mature miRs that are derived from the same precursor. All sequences are human.
- the level of at least one miR gene product can be measured in cells of a biological sample obtained from the subject.
- a tissue sample can be removed from a subject suspected of having lung cancer by conventional biopsy techniques.
- a blood sample can be removed from the subject, and white blood cells can be isolated for DNA extraction by standard techniques.
- the blood or tissue sample is preferably obtained from the subject prior to initiation of radiotherapy, chemotherapy or other therapeutic treatment.
- a corresponding control tissue or blood sample, or a control reference sample can be obtained from unaffected tissues of the subject, from a normal human individual or population of normal individuals, or from cultured cells corresponding to the majority of cells in the subject's sample.
- control tissue or blood sample is then processed along with the sample from the subject, so that the levels of miR gene product produced from a given miR gene in cells from the subject's sample can be compared to the corresponding miR gene product levels from cells of the control sample.
- a reference sample can be obtained and processed separately (e.g., at a different time) from the test sample and the level of a miR gene product produced from a given miR gene in cells from the test sample can be compared to the corresponding miR gene product level from the reference sample.
- the level of the at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is "up-regulated").
- expression of a miR gene product is "up-regulated” when the amount of miR gene product in a cell or tissue sample from a subject is greater than the amount of the same gene product in a control cell or tissue sample.
- the level of the at least one miR gene product in the test sample is less than the level of the corresponding miR gene product in the control sample (i.e., expression of the miR gene product is "down-regulated”).
- expression of a miR gene is “down- regulated” when the amount of miR gene product produced from that gene in a cell or tissue sample from a subject is less than the amount produced from the same gene in a control cell or tissue sample.
- the relative miR gene expression in the control and normal samples can be determined with respect to one or more RNA expression standards.
- the standards can comprise, for example, a zero miR gene expression level, the miR gene expression level in a standard cell line, the miR gene expression level in unaffected tissues of the subject, or the average level of miR gene expression previously obtained for a population of normal human controls.
- an alteration i. e., an increase or decrease in the level of a miR gene product in the sample obtained from the subject, relative to the level of a corresponding miR gene product in a control sample, is indicative of the presence of lung cancer in the subject.
- the level of at least one miR gene product in the test sample is greater than the level of the corresponding miR gene product in the control sample.
- the level of at least one miR gene product in the test sample is. less than the level of the corresponding miR gene product in the control sample.
- the at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR-205, miR-192-prec, miR-224, miR-126, miR-24-2, miR-30a-5p, miR-212.
- miR-140 miR-9, miR-214, miR-17-3p, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216- prec, miR-219-1, miR-106a, miR-197, miR-192, miR-125a-prec, miR-26a-l-prec, miR- 146, miR-203, miR-199b-prec, let-7a-2-prec, miR-27b, miR-32, miR-29b-2, miR-220, miR-33, miR-181c-prec, miR-150, miR-101-1, miR-124a-3, miR-125a and let-7f-l.
- the at least one miR gene product is selected from the group consisting of miR-21, miR-205 and miR-216.
- the lung cancer is a lung adenocarcinoma and the at least one miR gene product is selected from the group consisting of miR-21 , miR- 191, miR- 155, miR-210, miR- 126* and miR-224.
- the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-7i, miR-7-2, miR-7-3, miR-9, miR-9-1, miR-lOa, miR-15a, miR-15b, miR-16-1, miR-16-2, miR-17-5p, miR-20a, miR-21, miR-24-1, miR-24-2.
- the level of a miR gene product in a sample can be measured using any technique that is suitable for detecting RNA expression levels in a biological sample. Suitable techniques (e.g., Northern blot analysis, RT-PCR, in situ hybridization) for determining RNA expression levels in a biological sample (e.g., cells, tissues) are well known to those of skill in the art.
- the level of at least one miR gene product is detected using Northern blot analysis. For example, total cellular RNA can be purified from cells by homogenization in the presence of nucleic acid extraction buffer, followed by centrifugation. Nucleic acids are precipitated, and DNA is removed by treatment with DNase and precipitation.
- RNA molecules are then separated by gel electrophoresis on agarose gels according to standard techniques', and transferred to nitrocellulose filters.
- the RNA is then immobilized on the filters by heating. Detection and quantification of specific RNA is accomplished using appropriately labeled DNA or RNA probes complementary to the RNA in question. See, for example, Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., 2nd edition, Cold Spring Harbor Laboratory Press, 1989, Chapter 7, the entire disclosure of which is incorporated by reference.
- Suitable probes for Northern blot hybridization of a given miR gene product can be produced from the nucleic acid sequences provided in Table Ia and Table Ib and include, but are not limited to, probes having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% complementarity to a miR gene product of interest, as well as probes that have complete complementarity to a miR gene product of interest.
- Methods for preparation of labeled DNA and RNA probes, and the conditions for hybridization thereof to target nucleotide sequences, are described in Molecular Cloning: A Laboratory Manual, J.
- the nucleic acid probe can be labeled with, e.g., a radionuclide, such as 3 H, 32 P, 33 P, 14 C, or 35 S; a heavy metal; a ligand capable of functioning as a specific binding pair member for a labeled ligand (e.g., biotin, avidin or an antibody); a fluorescent molecule; a chemiluminescent molecule; an enzyme or the like. Probes can be labeled to high specific activity by either the nick translation method of Rigby et ⁇ l.
- Densitometric scanning of the photographic films exposed by the hybridized filters provides an accurate measurement of miR gene transcript levels.
- miR gene transcript levels can be quantified by computerized imaging systems, such as the Molecular Dynamics 400- B 2D Phosphorimager available from Amersham Biosciences, Piscataway, NJ.
- the random-primer method can be used to incorporate an analogue, for example, the dTTP analogue 5-(N-(N-biotinyl-epsilon-aminocaproyl)-3-aminoallyl)deoxyuridine triphosphate, into the probe molecule.
- biotinylated probe oligonucleotide can be detected by reaction with biotin-binding proteins, such as avidin, streptavidin and antibodies (e.g., anti-biotin antibodies) coupled to fluorescent dyes or enzymes that produce color reactions.
- biotin-binding proteins such as avidin, streptavidin and antibodies (e.g., anti-biotin antibodies) coupled to fluorescent dyes or enzymes that produce color reactions.
- determining the levels of RNA transcripts can be accomplished using the technique of in situ hybridization.
- This technique requires fewer cells than the Northern blotting technique and involves depositing whole cells onto a microscope cover slip and probing the nucleic acid content of the cell with a solution containing radioactive or otherwise labeled nucleic acid (e.g., cDNA or RNA) probes.
- This technique is particularly well- suited for analyzing tissue biopsy samples from subjects.
- the practice of the in situ hybridization technique is described in more detail in U.S. Patent No. 5,427,916, the entire disclosure of which is incorporated herein by reference.
- Suitable probes for in situ hybridization of a given miR gene product can be produced from the nucleic acid sequences provided in Table Ia and Table Ib, and include, but are not limited to, probes having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% complementarity to a miR gene product of interest, as well as probes that have complete complementarity to a miR gene product of interest, as described above.
- the relative number of miR gene transcripts in cells can also be determined by reverse transcription of miR gene transcripts, followed by amplification of the reverse- transcribed transcripts by polymerase chain reaction (RT-PCR).
- the levels of miR gene transcripts can be quantified in comparison with an internal standard, for example, the level of mRNA from a "housekeeping" gene present in the same sample.
- a suitable "housekeeping" gene for use as an internal standard includes, e.g., myosin or glyceraldehyde-3 -phosphate dehydrogenase (G3PDH).
- RNA e.g., at least 20 ⁇ g for each Northern blot
- autoradiographic techniques that require radioactive isotopes.
- an oligolibrary in microchip format (i.e., a microarray), may be constructed containing a set of oligonucleotide (e.g., oligodeoxynucleotide) probes that are specific for a set of miR genes.
- oligonucleotide e.g., oligodeoxynucleotide
- the expression level of multiple microRNAs in a biological sample can be determined by reverse transcribing the RNAs to generate a set of target • oligodeoxynucleotides, and hybridizing them to probe the oligonucleotides on the microarray to generate a hybridization, or expression, profile.
- probe oligonucleotide or “probe oligodeoxynucleotide” refers to an oligonucleotide that is capable of hybridizing to a target oligonucleotide.
- target oligonucleotide or “target oligodeoxynucleotide” refers to a molecule to be detected (e.g., via hybridization).
- miR-specific probe oligonucleotide or "probe oligonucleotide specific for a miR” is meant a probe oligonucleotide that has a sequence selected to hybridize to a specific miR gene product, or to a reverse transcript of the specific miR gene product.
- an "expression profile” or “hybridization profile” of a particular sample is essentially a fingerprint of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. That is, normal tissue may be distinguished from lung cancer tissue, and within lung cancer tissue, different prognosis states (for example, good or poor long term survival prospects) may be determined. By comparing expression profiles of lung cancer tissue in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.
- sequences that are differentially expressed in lung cancer tissue or normal lung tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated (e.g., to determine whether a chemotherapeutic drug acts to improve the long-term prognosis in a particular patient). Similarly, diagnosis may be done or confirmed by comparing patient samples with known expression profiles. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates that suppress the lung cancer expression profile or convert a poor prognosis profile to a better prognosis profile.
- the invention provides methods of diagnosing whether a subject has, or is at risk for developing, lung cancer, comprising reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample, wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, lung cancer.
- the microarray comprises miRNA- specif ⁇ c probe oligonucleotides for a substantial portion of all known human miRNAs.
- the microarray comprises miRNA-specific probe oligonucleotides for one or more miRNAs selected from the group consisting of miR- 21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR-205, miR-192-prec, miR- 224, miR-126, miR-24-2, miR-30a-5p, miR-212, miR-140, miR-9, miR-214, miR-17- 3p, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216-prec, miR-219-1, miR-106a, miR-197, miR-192, miR-125a-prec, miR-26a-l-prec, miR-146, miR-203,
- the microarray can be prepared from gene-specific oligonucleotide probes generated from known miRNA sequences.
- the array may contain two different oligonucleotide probes for each miRNA, one containing the active, mature sequence and the other being specific for the precursor of the miRNA.
- the array may also contain controls, such as one or more mouse sequences differing from human orthologs by only a few bases, which can serve as controls for hybridization stringency conditions.
- tRNAs and other RNAs e.g., rRNAs, mRNAs
- sequences are selected based upon the absence of any homology with any known miRNAs.
- the microarray may be fabricated using techniques known in the art. For example, probe oligonucleotides of an appropriate length, e.g., 40 nucleotides, are 5'- amine modified at position C6 and printed using commercially available microarray systems, e.g., the GeneMachine OmniGridTM 100 Microarrayer and Amersham CodeLinkTM activated slides. Labeled cDNA oligomer corresponding to the target RNAs is prepared by reverse transcribing the target RNA with labeled primer. Following first strand synthesis, the RNA/DNA hybrids are denatured to degrade the RNA templates.
- probe oligonucleotides of an appropriate length, e.g., 40 nucleotides, are 5'- amine modified at position C6 and printed using commercially available microarray systems, e.g., the GeneMachine OmniGridTM 100 Microarrayer and Amersham CodeLinkTM activated slides.
- the labeled target cDNAs thus prepared are then hybridized to the microarray chip under hybridizing conditions, e.g., 6X SSPE/30% formamide at 25°C for 18 hours, followed by washing in 0.75X TNT at 37 0 C for 40 minutes. At positions on the array where the immobilized probe DNA recognizes a complementary target cDNA in the sample, hybridization occurs.
- the labeled target cDNA marks the exact position on the array where binding occurs, allowing automatic detection and quantification.
- the output consists of a list of hybridization events, indicating the relative abundance of specific cDNA sequences, and therefore the relative abundance of the corresponding complementary miRs, in the patient sample.
- the labeled cDNA oligomer is a biotin-labeled cDNA, prepared from a biotin-labeled primer.
- the microarray is then processed by direct detection of the biotin-containing transcripts using, e.g., Streptavidin-Alexa647 conjugate, and scanned utilizing conventional scanning methods. Image intensities of each spot on the array are proportional to the abundance of the corresponding miR in the patient sample.
- the use of the array has several advantages for miRNA expression detection.
- the relatively limited number of miRNAs allows the construction of a common microarray for several species, with distinct oligonucleotide probes for each. Such a tool would allow for analysis of trans-species expression for each known miR under various conditions.
- a microchip containing miRNA-specific probe oligonucleotides corresponding to a substantial portion of the miRNome, preferably the entire miRNome. may be employed to carry out miR gene expression profiling, for analysis of miR expression patterns. Distinct miR signatures can be associated with established disease markers, or directly with a disease state.
- total RNA from a sample from a subject suspected of having a cancer is quantitatively reverse transcribed to provide a set of labeled target oligodeoxynucleotides complementary to the RNA in the sample.
- the target oligodeoxynucleotides are then hybridized to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the sample.
- the result is a hybridization profile for the sample representing the expression pattern of miRNA in the sample.
- the hybridization profile comprises the signal from the binding of the target oligodeoxynucleotides from the sample to the miRNA-specific probe oligonucleotides in the microarray.
- the profile may be recorded as the presence or absence of binding (signal vs. zero signal). More preferably, the profile recorded includes the intensity of the signal from each hybridization.
- the profile is compared to the hybridization profile generated from a normal, e.g.. noncancerous, control sample. An alteration in the signal is indicative of the presence of, or propensity to develop, cancer in the subject.
- the invention also provides methods of determining the prognosis of a subject with lung cancer, comprising measuring the level of at least one miR gene product, which is associated with a particular prognosis in lung cancer (e.g., a good or positive prognosis, a poor or adverse prognosis), in a test sample from the subject.
- a particular prognosis in lung cancer e.g., a good or positive prognosis, a poor or adverse prognosis
- an alteration in the level of a miR gene product that is associated with a particular prognosis, in the test sample, as compared to the level of a corresponding miR gene product in a control sample is indicative of the subject having a lung cancer with a particular prognosis.
- the miR gene product is associated with an adverse (i.e., poor) prognosis.
- an adverse prognosis include, but are not limited to, low survival rate and rapid disease progression.
- the at least one miR gene product associated with a particular prognosis is selected from the group consisting of miR-155, miR-17-3p, miR-106a, miR-93, let- 7a-2, miR- 145, let-7b, miR-20 and miR-21.
- the lung cancer is a lung adenocarcinoma and the at least one miR gene product associated with a particular prognosis is selected from the group consisting of miR-155 and let-7a-2.
- the level of the at least one miR gene product is measured by reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides, hybridizing the target oligodeoxynucleotides to a microarray that comprises miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample, and comparing the test sample hybridization profile to a hybridization profile generated from a control sample.
- the present invention encompasses methods of treating lung cancer in a subject, wherein at least one miR gene product is deregulated (e.g., down- regulated, up-regulated) in the cells (e.g., lung cancer cells) of the subject.
- the level of at least one miR gene product in a test sample is greater than the level of the corresponding miR gene product in a control sample. In another embodiment, the level of at least one miR gene product in a test sample (e.g., a lung cancer sample) is less than the level of the corresponding miR gene product in a control sample.
- the method comprises administering an effective amount of the at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, such that proliferation of cancer cells in the subject is inhibited.
- a miR gene product when a miR gene product is down-regulated in a cancer cell in a subject, administering an effective amount of an isolated miR gene product to the subject can inhibit proliferation of the cancer cell.
- the isolated miR gene product that is administered to the subject can be identical to an endogenous wild- type miR gene product (e.g., a miR gene product shown in Table Ia or Table Ib) that is down-regulated in the cancer cell or it can be a variant or biologically-active fragment thereof.
- a "variant" of a miR gene product refers to a miRNA that has less than 100% identity to a corresponding wild-type miR gene product and possesses one or more biological activities of the corresponding wild-type miR gene product.
- Such biological activities include, but are not limited to, inhibition of expression of a target RNA molecule (e.g., inhibiting translation of a target RNA molecule, modulating the stability of a target RNA molecule, inhibiting processing of a target RNA molecule) and inhibition of a cellular process associated with lung cancer (e.g., cell differentiation, cell growth, cell death).
- These variants include species variants and variants that are the consequence of one or more mutations (e.g., a substitution, a deletion, an insertion) in a miR gene.
- the variant is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a corresponding wild-type miR gene product.
- a "biologically-active fragment" of a miR gene product refers to an RNA fragment of a miR gene product that possesses one or more biological activities of a corresponding wild-type miR gene product.
- biological activities include, but are not limited to, inhibition of expression of a target RNA molecule and inhibition of a cellular process associated with lung cancer.
- the biologically-active fragment is at least about 5, 7, 10, 12, 15, or 17 nucleotides in length.
- an isolated miR gene product can be administered to a subject in combination with one or more additional anti-cancer treatments. Suitable anti-cancer treatments include, but are not limited to, chemotherapy, radiation therapy and combinations thereof (e.g., chemoradiation).
- the method comprises administering to the subject an effective amount of a compound that inhibits expression of the at least one miR gene product, such that proliferation of lung cancer cells is inhibited.
- a compound that inhibits expression of the at least one miR gene product such that proliferation of lung cancer cells is inhibited.
- Such compounds are referred to herein as miR gene expression-inhibition compounds.
- suitable miR gene expression-inhibition compounds include, but are not limited to, those described herein (e.g., double-stranded RNA, antisense nucleic acids and enzymatic RNA molecules).
- a miR gene expression-inhibiting compound can be administered to a subject in combination with one or more additional anti-cancer treatments. Suitable anti-cancer treatments include, but are not limited to, chemotherapy, radiation therapy and combinations thereof (e.g., chemoradiation).
- the isolated miR gene product that is deregulated in lung cancer is selected from the group consisting of miR-21, miR-191, miR-126*, miR- 210, miR-155, miR-143, miR-205, miR-192-prec, miR-224, miR-126, miR-24-2, miR- 30a-5p, miR-212, miR- 140, miR-9, miR-214, miR-17-3p, miR- 124a- 1, miR-218-2, miR-95, miR-145.
- the at least one miR gene product is selected from the group consisting of miR-21, miR-205 and miR- 216.
- the lung cancer is a lung adenocarcinoma and the at least one miR gene product is selected from the group consisting of miR-21, miR-191, miR- 155, miR-210, miR-126* and miR-224.
- the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-7i, miR-7-2, miR-7-3, miR-9, miR-9-1, miR-10a, miR-15a, miR-15b, miR-16-1, miR-16-2, miR-17-5 ⁇ , miR-20a, miR-21, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30, miR-30a-5 ⁇ , miR-30c, miR-30d, miR-31, miR-32, miR-34, miR- 34a, miR-34apree, miR-34a-l, miR-34a-2, miR-92-2, miR-96, miR-99a, miR-99b prec, miR-100, miR-103, miR-106a, miR-107, miR-123, miR-124a-l, miR-125b-l, miR-125b-2, miR-
- miR-199a-l miR-199a-2, miR- 199b, miR-200b, miR-202, miR-203, miR-204, miR-205, miR-210, miR-211, miR-212, miR-214, miR-215, miR-217, miR-221 and/or miR-223.
- treat refers to ameliorating symptoms associated with a disease or condition, for example, lung cancer, including preventing or delaying the onset of the disease symptoms, and/or lessening the severity or frequency of symptoms of the disease or condition.
- subject and “individual” are defined herein to include animals, such as mammals, including, but not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent, or murine species.
- the animal is a human.
- an "effective amount" of an isolated miR gene product is an amount sufficient to inhibit proliferation of a cancer cell in a subject suffering from lung cancer.
- an effective amount of a miR gene product to be administered to a given subject by taking into account factors, such as the size and weight of the subject; the extent of disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.
- an effective amount of an isolated miR gene product can be based on the approximate weight of a tumor mass to be treated.
- the approximate weight of a tumor mass can be determined by calculating the approximate volume of the mass, wherein one cubic centimeter of volume is roughly equivalent to one gram.
- An effective amount of the isolated miR gene product based on the weight of a tumor mass can be in the range of about 10-500 micrograms/gram of tumor mass.
- the tumor mass can be at least about 10 micrograms/gram of tumor mass, at least about 60 micrograms/gram of tumor mass or at least about 100 micrograms/gram of tumor mass.
- an effective amount of an isolated miR gene product can also be based on the approximate or estimated body weight of a subject to be treated. Preferably, such effective amounts are administered parenterally or enterally, as described herein.
- an effective amount of the isolated miR gene product that is administered to a subject can range from about 5 — 3000 micrograms/kg of body weight, from about 700 - 1000 micrograms/kg of body weight, or greater than about 1000 micrograms/kg of body weight.
- One skilled in the art can also readily determine an appropriate dosage regimen for the administration of an isolated miR gene product to a given subject.
- a miR gene product can be administered to the subject once (e.g., as a single injection or deposition).
- a miR gene product can be administered once or twice daily to a subject for a period of from about three to about twenty-eight days, more particularly from about seven to about ten days.
- a miR gene product is administered once a day for seven days.
- the effective amount of the miR gene product administered to the subject can comprise the total amount of gene product administered over the entire dosage regimen.
- an "isolated" miR gene product is one that is synthesized, or altered or removed from the natural state through human intervention.
- a synthetic miR gene product or a miR gene product partially or completely separated from the coexisting materials of its natural state, is considered to be "isolated.”
- An isolated miR gene product can exist in a substantially-purified form, or can exist in a cell into which the miR gene product has been delivered.
- a miR gene product that is deliberately delivered to, or expressed in, a cell is considered an "isolated” miR gene product.
- a miR gene product produced inside a cell from a miR precursor molecule is also considered to be an "isolated” molecule.
- the isolated miR gene products described herein can be used for the manufacture of a medicament for treating lung cancer in a subject (e.g., a human).
- Isolated miR gene products can be obtained using a number of standard techniques.
- the miR gene products can be chemically synthesized or recombinantly produced using methods known in the art.
- miR gene products are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer.
- RNA molecules or synthesis reagents include, e.g., Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, CO, U.S.A.), Pierce Chemical (part of Perbio Science, Rockford, IL, U.S.A.), Glen Research (Sterling, VA, U.S.A.), ChemGenes (Ashland, MA, U.S.A.) and Cruachem (Glasgow, UK).
- the miR gene products can be expressed from recombinant circular or linear DNA plasmids using any suitable promoter.
- suitable promoters for expressing RNA from a plasmid include, e.g., the U6 or Hl RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art.
- the recombinant plasmids of the invention can also comprise inducible or regulatable promoters for expression of the miR gene products in cancer cells.
- the miR gene products that are expressed from recombinant plasmids can be isolated from cultured cell expression systems by standard techniques.
- the miR gene products that are expressed from recombinant plasmids can also be delivered to, and expressed directly in, the cancer cells.
- the use of recombinant plasmids to deliver the miR gene products to cancer cells is discussed in more detail below.
- the miR gene products can be expressed from a separate recombinant plasmid, or they can be expressed from the same recombinant plasmid.
- the miR gene products are expressed as RNA precursor molecules from a single plasmid, and the precursor molecules are processed into the functional miR gene product by a suitable processing system, including, but not limited to, processing systems extant within a cancer cell.
- processing systems include, e.g., the in vitro • Drosophila cell lysate system (e.g., as described in U.S. Published Patent Application No. 2002/0086356 to Tuschl et al., the entire disclosure of which is incorporated herein by reference) and the E. coli RNAse III system (e.g., as described in U.S. Published Patent Application No. 2004/0014113 to Yang et al., the entire disclosure of which is incorporated herein by reference).
- the in vitro • Drosophila cell lysate system e.g., as described in U.S. Published Patent Application No. 2002/0086356 to Tuschl et al., the entire disclosure of which is incorporated herein by reference
- E. coli RNAse III system e.g., as described in U.S. Published Patent Application No. 2004/0014113 to Yang et al., the entire disclosure of which is incorporated herein by reference.
- plasmids suitable for expressing the miR gene products are within the skill in the art. See, for example, Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat. Biotechnol, 20:446-448; Brummelkamp et al. (2002), Science 296:550-553; Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al. (2002), Genes Dev. 16:948-958; Lee ei al. (2002), Nat. Biotechnol. 20:500-505; and Paul et al. (2002), Nat. Biotechnol. 20:505-508, the entire disclosures of which are incorporated herein by reference.
- a plasmid expressing the miR gene products comprises a sequence encoding a miR precursor RNA under the control of the CMV intermediate- early promoter.
- "under the control" of a promoter means that the nucleic acid sequences encoding the miR gene product are located 3' of the promoter, so that the promoter can initiate transcription of the miR gene product coding sequences.
- the miR gene products can also be expressed from recombinant viral vectors. It is contemplated that the miR gene products can be expressed from two separate recombinant viral vectors, or from the same viral vector.
- the RNA expressed from the recombinant viral vectors can either be isolated from cultured cell expression systems by standard techniques, or can be expressed directly in cancer cells. The use of recombinant viral vectors to deliver the miR gene products to cancer cells is discussed in more detail below.
- the recombinant viral vectors of the invention comprise sequences encoding the miR gene products and any suitable promoter for expressing the RNA sequences.
- suitable promoters include, but are not limited to, the U6 or Hl RNA pol III promoter sequences, or the cytomegalovirus promoters. Selection of other suitable promoters is within the skill in the art.
- the recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the miR gene products in a cancer cell.
- Any viral vector capable of accepting the coding sequences for the miR gene products can be used; for example, vectors derived from adenovirus (AV); adeno- associated virus (AAV); retroviruses ⁇ e.g., lentiviruses (LV), Rhabdo viruses, murine leukemia virus); herpes virus, and the like.
- AV adenovirus
- AAV adeno- associated virus
- retroviruses ⁇ e.g., lentiviruses (LV), Rhabdo viruses, murine leukemia virus
- herpes virus and the like.
- the tropism of the viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.
- lentiviral vectors of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV) 3 rabies, Ebola, Mokola, and the like.
- AAV vectors of the invention can be made to target different cells by engineering the vectors to express different capsid protein serotypes.
- an AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2.
- This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector.
- AAV vectors that express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz, J.E., et al (2002), J. Virol. 76:791-801, the entire disclosure of which is incorporated herein by reference.
- Particularly suitable viral vectors are those derived from AV and AAV.
- a suitable AV vector for expressing the miR gene products, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells are described in Xia et al. (2002), Nat. Biotech. 20:1006-1010, the entire disclosure of which is incorporated herein by reference.
- Suitable AAV vectors for expressing the miR gene products, methods for constructing the recombinant AAV vector, and methods for delivering the vectors into target cells are described in Samulski et al. (1987), J. Virol. 61:3096-3101; Fisher et al. (1996), J. Virol, 70:520-532; Samulski et al. (1989), J Virol. 63:3822-3826; U.S. Patent No. 5,252,479; U.S. Patent No.
- the miR gene products are expressed from a single recombinant AAV vector comprising the CMV intermediate early promoter.
- a recombinant AAV viral vector of the invention comprises a nucleic acid sequence encoding a miR precursor RNA in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
- operable connection with a polyT termination sequence means that the nucleic acid sequences encoding the sense or antisense strands are immediately adjacent to the polyT termination signal in the 5' direction. During transcription of the miR sequences from the vector, the polyT termination signals act to terminate transcription.
- an effective amount of at least one compound that inhibits miR expression can be administered to the subject.
- inhibiting miR expression means that the production of the precursor and/or active, mature form of miR gene product after treatment is less than the amount produced prior to treatment.
- One skilled in the art can readily determine whether miR expression has been inhibited in a cancer cell, using, for example, the techniques for determining miR transcript level discussed herein. Inhibition can occur at the level of gene expression (i.e., by inhibiting transcription of a miR gene encoding the miR gene product) or at the level of processing (e.g., by inhibiting processing of a miR precursor into a mature, active miR).
- an "effective amount" of a compound that inhibits miR expression is an amount sufficient to inhibit proliferation of a cancer cell in a subject suffering from a cancer (e.g., lung cancer).
- a cancer e.g., lung cancer.
- One skilled in the art can readily determine an effective amount of a miR expression-inhibiting compound to be administered to a given subject, by taking into account factors, such as the size and weight of the subject; the extent of disease penetration; the age, health and sex of the subject; the route of administration; and whether the administration is regional or systemic.
- an effective amount of the expression-inhibiting compound can be based on the approximate weight of a tumor mass to be treated, as described herein.
- An effective amount of a compound that inhibits miR expression can also be based on the approximate or estimated body weight of a subject to be treated, as described herein.
- RNA molecules such as ribozymes.
- siRNA short- or small-interfering RNA
- enzymatic RNA molecules such as ribozymes.
- Each of these compounds can be targeted to a given miR gene product and interfere with the expression (e.g., by inhibiting translation, by inducing cleavage and/or degradation) of the target miR gene product.
- RNA interference of the miR gene can be inhibited by inducing RNA interference of the miR gene with an isolated double-stranded RNA (“dsRNA") molecule which has at least 90%, for example at least 95%, at least 98%, at least 99%, or 100%, sequence homology with at least a portion of the miR gene product.
- the dsRNA molecule is a "short or small interfering RNA" or "siRNA.”
- siRNA useful in the present methods comprise short double-stranded RNA from about 17 nucleotides to about 29 nucleotides in length, preferably from about 19 to about 25 nucleotides in length.
- the siRNA comprise a sense RNA strand and a complementary antisense RNA strand annealed together by standard Watson-Crick base-pairing interactions (hereinafter "base-paired")-
- the sense strand comprises a nucleic acid sequence that is substantially identical to a nucleic acid sequence contained within the target miR gene product.
- a nucleic acid sequence in an siRNA that is "substantially identical" to a target sequence contained within the target mRNA is a nucleic acid sequence that is identical to the target sequence, or that differs from the target sequence by one or two nucleotides.
- the sense and antisense strands of the siRNA can comprise two complementary, single-stranded RNA molecules, or can comprise a single molecule in which two complementary portions are base-paired and are covalently linked by a single-stranded "hairpin" area.
- the siRNA can also be altered RNA that differs from naturally-occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides.
- Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or to one or more internal nucleotides of the siRNA, or modifications that make the siRNA resistant to nuclease digestion, or the substitution of one or more nucleotides in the siRNA with deoxyribonucleotides.
- the siRNA can also comprise a 3' overhang.
- a "3' overhang” refers to at least one unpaired nucleotide extending from the 3'- end of a duplexed RNA strand.
- the siRNA comprises at least one 3' overhang of from 1 to about 6 nucleotides (which includes ribonucleotides or deoxyribonucleotides) in length, from 1 to about 5 nucleotides in length, from 1 to about 4 nucleotides in length, or from about 2 to about 4 nucleotides in length.
- the 3' overhang is present on both strands of the SiRNA 1 ; and is 2 nucleotides in length.
- each strand of the siRNA can comprise 3' overhangs of dithymidylic acid ("TT") or diuridylic acid (“uu").
- the siRNA can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products.
- Exemplary methods for producing and testing dsRNA or siRNA molecules are described in U.S. Published Patent Application No. 2002/0173478 to Gewirtz and in U.S . Published Patent Application No. 2004/0018176 to Reich et al, the entire disclosures of both of which are incorporated herein by reference.
- an antisense nucleic acid refers to a nucleic acid molecule that binds to target RNA by means of RNA-RNA, RNA-DNA or RNA-peptide nucleic acid interactions, which alters the activity of the target RNA.
- Antisense nucleic acids suitable for use in the present methods are single-stranded nucleic acids (e.g., RNA, DNA, RNA-DNA chimeras, peptide nucleic acids (PNA)) that generally comprise a nucleic acid sequence complementary to a contiguous nucleic acid sequence in a miR gene product.
- the antisense nucleic acid can comprise a nucleic acid sequence that is 50-100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in a miR gene product. Nucleic acid sequences of particular human miR gene products are provided in Table Ia and Table Ib. Without wishing to be bound by any theory, it is believed that the antisense nucleic acids activate RNase H or another cellular nuclease that digests the miR gene product/antisense nucleic acid duplex.
- Antisense nucleic acids can also contain modifications to the nucleic acid backbone or to the sugar and base moieties (or their equivalent) to enhance target specificity, nuclease resistance, delivery or other properties related to efficacy of the molecule.
- modifications include cholesterol moieties, duplex intercalators, such as acridine, or one or more nuclease-resistant groups.
- Antisense nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products. Exemplary methods for producing and testing are within the skill in the art; see, e.g., Stein and Cheng (1993), Science 261 : 1004 and U.S. Patent No. 5,849,902 to Woolf et ah, the entire disclosures of which are incorporated herein by reference.
- an "enzymatic nucleic acid” refers to a nucleic acid comprising a substrate binding region that has complementarity to a contiguous nucleic acid sequence of a miR gene product, and which is able to specifically cleave the miR gene product.
- the enzymatic nucleic acid substrate binding region can be, for example, 50- 100% complementary, 75-100% complementary, or 95-100% complementary to a contiguous nucleic acid sequence in a miR gene product.
- the enzymatic nucleic acids can also comprise modifications at the base, sugar, and/or phosphate groups.
- An exemplary enzymatic nucleic acid for use in the present methods is a ribozyme.
- the enzymatic nucleic acids can be produced chemically or biologically, or can be expressed from a recombinant plasmid or viral vector, as described above for the isolated miR gene products.
- exemplary methods for producing and testing dsRNA or siRNA molecules are described in Werner and Uhlenbeck (1995), Nucl. Acids Res. 23:2092-96; Hammann ⁇ ?? ⁇ /. (1999), Antisense and Nucleic Acid Drug Dev. 9:25-31; and U.S. Patent No. 4,987,071 to Cech et al, the entire disclosures of which are incorporated herein by reference.
- Administration of at least one miR gene product, or at least one compound for inhibiting miR expression will inhibit the proliferation of cancer cells in a subject who has a cancer (e.g., lung cancer).
- a cancer e.g., lung cancer
- to "inhibit the proliferation of a cancer cell” means to kill the cell, or permanently or temporarily arrest or slow the growth of the cell.
- Inhibition of cancer cell proliferation can be inferred if the number of such cells in the subject remains constant or decreases after administration of the miR gene products or miR gene expression- inhibiting compounds.
- An inhibition of cancer cell proliferation can also be inferred if the absolute number of such cells increases, but the rate of tumor growth decreases.
- the number of cancer cells in the body of a subject can be determined by direct measurement, or by estimation from the size of primary or metastatic tumor masses.
- the number of cancer cells in a subject can be measured by immunohistological methods, flow cytometry, or other techniques designed to detect characteristic surface markers of cancer cells.
- the size of a tumor mass can be ascertained by direct visual observation, or by diagnostic imaging methods, such as X-ray, magnetic resonance imaging, ultrasound, and scintigraphy. Diagnostic imaging methods used to ascertain size of the tumor mass can be employed with or without contrast agents, as is known in the art.
- the size of a tumor mass can also be ascertained by physical means, such as palpation of the tissue mass or measurement of the tissue mass with a measuring instrument, such as a caliper.
- the miR gene products or miR gene expression-inhibiting compounds can be administered to a subject by any means suitable for delivering these compounds to cancer cells of the subject.
- the miR gene products or miR expression- inhibiting compounds can be administered by methods suitable to transfect cells of the subject with these compounds, or with nucleic acids comprising sequences encoding these compounds.
- the cells are transfected with a plasmid or viral vector comprising sequences encoding at least one miR gene product or miR gene expression-inhibiting compound.
- Transfection methods for eukaryotic cells include, e.g., direct injection of the nucleic acid into the nucleus or pronucleus of a cell; electroporation; liposome transfer or transfer mediated by lipophilic materials; receptor-mediated nucleic acid delivery, bioballistic or particle acceleration; calcium phosphate precipitation, and transfection mediated by viral vectors.
- cells can be transfected with a liposomal transfer compound, e.g., DOTAP (N-[I -(2,3 -dioleoyloxy)propyl]-N 3 N,N-trimethyl-ammonium methylsulfate, Boehringer-Mannheim) or an equivalent, such as LIPOFECTIN.
- DOTAP N-[I -(2,3 -dioleoyloxy)propyl]-N 3 N,N-trimethyl-ammonium methylsulfate, Boehringer-Mannheim
- LIPOFECTIN LIPOFECTIN
- a miR gene product or miR gene expression-inhibiting compound can also be administered to a subject by any suitable enteral or parenteral administration route.
- Suitable enteral administration routes for the present methods include, e.g., oral, rectal, or intranasal delivery.
- Suitable parenteral administration routes include, e.g., intravascular administration (e.g., intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue injection (e.g., peri-tumoral and intra-tumoral injection, intra-retinal injection, or subretinal injection); subcutaneous injection or deposition, including subcutaneous infusion (such as by osmotic pumps); direct application to the tissue of interest, for example by a catheter or other placement device (e.g. , a retinal pellet or a suppository or an implant comprising a porous, non-porous, or gelatinous material); and inhalation.
- Particularly suitable administration routes are injection, infusion and direct injection into the tumor.
- a miR gene product or miR gene product expression- inhibiting compound can be administered to the subject either as naked RNA, in combination with a delivery reagent, or as a nucleic acid (e.g., a recombinant plasmid or viral vector) comprising sequences that express the miR gene product or miR gene expression-inhibiting compound.
- Suitable delivery reagents include, e.g., the Minis Transit TKO lipophilic reagent; LIPOFECTIN; lipofectamine; cellfectin; polycations (e.g., polylysine) and liposomes.
- Recombinant plasmids and viral vectors comprising sequences that express the miR gene products or miR gene expression-inhibiting compounds, and techniques for delivering such plasmids and vectors to cancer cells, are discussed herein and/or are well known in the art.
- liposomes are used to deliver a miR gene product or miR gene expression-inhibiting compound (or nucleic acids comprising sequences encoding them) to a subject.
- Liposomes can also increase the blood half-life of the gene products or nucleic acids.
- Suitable liposomes for use in the invention can be formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of factors, such as the desired liposome size and half-life of the liposomes in the blood stream.
- a variety of methods are known for preparing liposomes, for example, as described in Szoka et al. (1980), Ann. Rev. Biophys. Bioeng. 9:467; and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are incorporated herein by reference.
- the liposomes for use in the present methods can comprise a ligand molecule that targets the liposome to cancer cells.
- Ligands that bind to receptors prevalent in cancer cells such as monoclonal antibodies that bind to tumor cell antigens, are preferred.
- the liposomes for use in the present methods can also be modified so as to avoid clearance by the mononuclear macrophage system ("MMS") and reticuloendothelial system ("RES").
- MMS mononuclear macrophage system
- RES reticuloendothelial system
- modified liposomes have opsonization- inhibition moieties on the surface or incorporated into the liposome structure.
- a liposome of the invention can comprise both an opsonization-inhibition moiety and a ligand.
- Opsonization-inhibiting moieties for use in preparing the liposomes of the invention are typically large hydrophilic polymers that are bound to the liposome membrane.
- an opsonization-inhibiting moiety is "bound" to a liposome membrane when it is chemically or physically attached to the membrane, e.g., by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of membrane lipids.
- These opsonization-inhibiting hydrophilic polymers form a protective surface layer that significantly decreases the uptake of the liposomes by the MMS and RES; e.g., as described in U.S. Patent No. 4,920,016, the entire disclosure of which is incorporated herein by reference.
- Opsonization-inhibiting moieties suitable for modifying liposomes are preferably water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, and more preferably from about 2,000 to about 20,000 daltons.
- Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) or derivatives thereof; e.g., methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers, such as polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, e.g., polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GMl.
- PEG polyethylene glycol
- PPG polypropylene glycol
- synthetic polymers such as polyacrylamide
- Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable.
- the opsonization-inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyleneamine. or polynucleotide.
- the opsonization-inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, e.g., galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; aminated polysaccharides or oligosaccharides (linear or branched); or carboxylated polysaccharides or oligosaccharides, e.g., reacted with derivatives of carbonic acids with resultant linking of carboxylic groups.
- the opsonization-inhibiting moiety is a PEG, PPG, or a derivative thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called "PEGylated liposomes.”
- the opsonization-inhibiting moiety can be bound to the liposome membrane by any one of numerous well-known techniques.
- an N-hydroxysuccinimide ester of PEG can be bound to a phosphatidyl-ethanolamine lipid-soluble anchor, and then bound to a membrane.
- a dextran polymer can be derivatized with a stearylamine lipid-soluble anchor via reductive amination using Na(CN)BH 3 and a solvent mixture, such as tetrahydrofuran and water in a 30:12 ratio at 60 0 C.
- Liposomes modified with opsonization-inhibition moieties remain in the circulation much longer than unmodified liposomes. For this reason, such liposomes are sometimes called "stealth” liposomes. Stealth liposomes are known to accumulate in tissues fed by porous or "leaky” microvasculature. Thus, tissue characterized by such microvasculature defects, for example, solid tumors (e.g., lung cancers), will efficiently accumulate these liposomes; see Gabizon, et al. (1988), Proc. Natl. Acad. ScL, U.S.A., 18:6949-53.
- liposomes that are modified with opsonization-inhibition moieties are particularly suited to deliver the miR gene products or miR gene expression-inhibition compounds (or nucleic acids comprising sequences encoding them) to tumor cells.
- the miR gene products or miR gene expression-inhibition compounds can be formulated as pharmaceutical compositions, sometimes called "medicaments," prior to administering them to a subject, according to techniques known in the art. Accordingly, the invention encompasses pharmaceutical compositions for treating lung cancer.
- the pharmaceutical composition comprises at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, and a pharmaceutically-acceptable carrier.
- the at least one miR gene product corresponds to a miR gene product that has a decreased level of expression in lung cancer cells relative to suitable control cells.
- the isolated miR gene product is selected from the group consisting of miR-126*, miR-192, miR-224, miR-126, miR-30a-5p, miR-140, miR-9, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, miR-216, miR-219-1, miR-125a, miR-26a-l, miR-199b, let-7a-2, miR-27b, miR-32, miR-29b-2, miR-220, miR-33, miR-181c, miR- 101-1, miR- 124a-3 , miR- 125b- 1 , let-7f- 1 and a combination thereof.
- the isolated miR gene product is not miR-15a or miR-16-1. In an additional embodiment, the miR gene product is not miR-210 or miR-212. In another embodiment, the miR gene product is not miR-21, miR-143, miR-205 or miR-9. In yet another embodiment, the miR gene product is not miR-21, miR-191, miR-126*, miR- 210, miR-155, miR-143, miR-205, miR-126, miR-30a-5 ⁇ , miR-140, miR-214, miR- 218-2, miR-145, miR-106a, miR-192, miR-203, miR-150, miR-220, miR-212 or miR- 9.
- the pharmaceutical compositions of the invention comprise at least one miR expression-inhibition compound.
- the at least one miR gene expression-inhibition compound is specific for a miR gene whose expression is greater in lung cancer cells than control cells.
- the miR gene expression-inhibition compound is specific for one or more miR gene products selected from the group consisting of miR-21, miR-191, miR-210, miR-155, miR-205, miR-24-2, miR-212, miR-214, miR-17-3p, miR-106a, miR-197, miR-192, miR-146, miR-203, miR-150 and a combination thereof.
- the isolated miR gene product is not specific for miR- 15a or miR- 16-1. In an additional embodiment, the miR gene product is not specific for miR-210 or miR-212. . In another embodiment, the miR gene product is not specific for miR-21, miR- 143, miR-205 or miR-9.
- the miR gene product is not specific for miR-21, miR-191, miR-126*, miR-210, miR-155, miR-143, miR-205, miR-126, miR-30a-5p, miR-140, miR-214, miR-218-2, miR-145, miR-106a, miR-192, miR-203, miR-150, miR-220, miR-212 or miR-9.
- Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free.
- pharmaceutical compositions include formulations for human and veterinary use.
- compositions of the invention are within the skill in the art, for example, as described in Remington's Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, PA. (1985), the entire disclosure of which- is incorporated herein by reference.
- the present pharmaceutical compositions comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression- inhibition compound) (e.g., 0.1 to 90% by weight), or a physiologically-acceptable salt thereof, mixed with a pharmaceutically-acceptable carrier.
- the pharmaceutical composition of the invention additionally comprises one or more anticancer agents (e.g., chemotherapeutic agents).
- the pharmaceutical formulations of the invention can also comprise at least one miR gene product or miR gene expression- inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound), which are encapsulated by liposomes and a pharmaceutically-acceptable carrier.
- the pharmaceutical composition comprises a miR gene or gene product that is not miR- 15, miR- 16, miR-143 and/or miR-145.
- suitable pharmaceutically-acceptable carriers are water, buffered water, normal saline, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.
- the pharmaceutical compositions of the invention comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the riiiR gene product or miR gene expression-inhibition compound) that is resistant to degradation by nucleases.
- nucleic acids that are nuclease resistant, for example by incorporating one or more ribonucleotides that is modified at the 2 '-position into the miR gene product.
- Suitable 2 '-modified ribonucleotides include those modified at the 2'-position with fiuoro, amino, alkyl, alkoxy and O-allyl.
- compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives.
- Suitable pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH adjusting agents.
- Suitable additives include, e.g., physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA or DTPA-bisamide) or calcium chelate complexes (such as, for example, calcium DTPA, CaNaDTP A-bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate).
- Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.
- conventional nontoxic solid pharmaceutically-acceptable carriers can be used; for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
- a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%, preferably 25%- 75%, of the at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising sequences encoding them).
- a pharmaceutical composition for aerosol (inhalational) administration can comprise 0.01-20% by weight, preferably l%-10% by weight, of the at least one miR gene product or miR gene expression-inhibition compound (or at least one nucleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) encapsulated in a liposome as described above, and a propellant.
- a carrier can also be included as desired; e.g., lecithin for intranasal delivery.
- the pharmaceutical compositions of the invention can further comprise one or more anti-cancer agents.
- the compositions comprise at least one miR gene product or miR gene expression-inhibition compound (or at least one nueleic acid comprising a sequence encoding the miR gene product or miR gene expression-inhibition compound) and at least one chemotherapeutic agent.
- Chemotherapeutic agents that are suitable for the methods of the invention include, but are not limited to, DNA-alkylating agents, anti-tumor antibiotic agents, anti-metabolic agents, tubulin stabilizing agents, tubulin destabilizing agents, hormone antagonist agents, topoisomerase inhibitors, protein kinase inhibitors, HMG-CoA inhibitors, CDK inhibitors, cyclin inhibitors, caspase inhibitors, metalloproteinase inhibitors, antisense nucleic acids, triple-helix DNAs, nucleic acids aptamers, and molecularly-modified viral, bacterial and exotoxic agents.
- Suitable agents for the compositions of the present invention include, but are not limited to, cytidine arabinoside, methotrexate, vincristine, etoposide (VP- 16), doxorubicin (adriamycin), cisplatin (CDDP), dexamethasone, arglabin, cyclophosphamide, sarcolysin, methylnitrosourea, fluorouracil, 5-fluorouracil (5FU), vinblastine, camptothecin, actinomycin-D, mitomycin C, hydrogen peroxide, oxaliplatin, irinotecan, topotecan, leucovorin, carmustine, streptozocin, CPT-11, taxol, tamoxifen, dacarbazine, rituximab, daunorubicin, 1- ⁇ -D-arabinofuranosylcytosine, imatinib, fludarabine, docetaxe
- the invention also encompasses methods of identifying an anti-lung cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product in the cell.
- the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in lung cancer cells.
- An increase in the level of the miR gene product in the cell, relative to a suitable control e.g., the level of the miR gene product in a control cell, is indicative of the test agent being an anti-lung cancer agent.
- the at least one miR gene product associated with decreased expression levels in lung cancer cells is selected from the group consisting of miR-126*, miR-192, miR-224, miR-126, miR-30a-5p, miR-140, miR-9, miR-124a-l, miR-218-2, miR-95, miR-145, miR-198, m ⁇ R-216, miR-219-1, miR-125a, miR-26a-l, miR-199b, let-7a-2, miR-27b, miR-32, miR-29b-2, miR-220, miR-33, miR-181c, miR- 101-1, miR- 124a-3 , miR- 125b- 1 , let-7f- 1 and a combination thereof.
- the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-7i, miR-7-2, miR-7-3, miR-9, miR-9-1, miR-10a, miR-15a, miR-15b, miR-16-1, miR- 16- 2, miR-17-5p, miR-20a, miR-21, miR-24-1, miR-24-2, miR-25, miR-29b-2, miR-30, miR-30a-5p, miR-30c, miR-30d, miR-31, miR-32, miR-34, miR-34a, miR-34a prec, miR-34a-l, miR-34a-2, miR-92-2, miR-96, miR-99a, miR-99b prec, miR- 100, miR- 103, miR-106a, miR-107, miR-123, miR-124a-l, miR-125b-l, miR-125b-2, miR-
- the method comprises providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in lung cancer cells.
- a decrease in the level of the miR gene product in the cell, relative to a suitable control is indicative of the test agent being an anti-lung cancer agent.
- At least one miR gene product associated with increased expression levels in lung cancer cells is selected from the group consisting of miR-21, miR-191, miR-210, miR-155, miR-205, miR-24-2, miR-212, miR-214, miR-17-3p, miR-106a, miR-197, miR-192, miR-146, miR-203, miR-150 and a combination thereof.
- the miR gene product is not one or more of let7a-2, let-7c, let-7g, let-7i, miR-7-2, miR-7-3, miR-9, miR-9-1, miR- 10a, miR- 15a, miR- 15b, miR- 16-1, miR- 16-2, miR- 17-5p, miR-20a, miR-21 , miR-24- 1 , miR-24-2, miR-25, miR- 29b-2, miR-30, miR-30a-5p, miR-30c, miR-30d, miR-31, miR-32, miR-34, miR-34a, miR-34a prec, miR-34a-l, miR-34a-2, miR-92-2, miR-96, miR-99a, miR-99b prec, miR-100, miR-103, miR-106a, miR-107, miR-123, miR-124a-l, miR-125b-l, miR-
- miR- 149 miR-153, miR-155, miR 159-1, miR-181, miR-181b-l, miR-182, miR-186, miR- 191, miR-192, miR-195, miR-196-1, miR-196-1 prec, miR-196-2, miR-199a-l, miR- 199a-2 5 miR-199b, miR-200b, miR-202, miR-203, miR-204, miR-205, miR-210, miR- 211, miR-212, miR-214, miR-215, miR-217, miR-221 and/or miR-223.
- Suitable agents include, but are not limited to drugs (e.g., small molecules, peptides), and biological macromolecules (e.g., proteins, nucleic acids).
- the agent can be produced recombinantly, synthetically, or it may be isolated (i.e., purified) from a natural source.
- Various methods for providing such agents to a cell e.g., transfection
- Methods for detecting the expression of at least one miR gene product e.g., Northern blotting, in situ hybridization, RT-PCR, expression profiling
- Several of these methods are also described herein.
- Example 1 Altered miRNA expression in primary lung cancers Materials and methods Samples
- RNA from tissues was isolated by TRIzol ® Reagent (Invitrogen), according to the manufacturer's instructions.
- RNA microarray analysis was performed as previously described (Liu, C.G., et al., Proc. Natl. Acad. Sci. U.S.A. 101:9740-9744 (2004)). Briefly, 5 ⁇ g of total RNA was hybridized with miRNA microarray chips containing 352 probes in triplicate. Specifically, these chips contain gene-specific 40-mer oligonucleotide probes, spotted by contacting technologies and covalently attached to a polymeric matrix, which were generated from 161 human miRNAs, 84 mouse miRNAs, miRNAs from three other species and tRNA.
- microarrays were hybridized in 6X SSPE (0.9 M NaCl/60 mM NaH 2 PO 4 -H 2 O/8 mM EDTA, pH 7.4)/30% formamide at 25°C for 18 hr, washed in 0.75X TNT (Tris-HCl/NaCl/Tween 20) at 37 0 C for 40 min, and processed using a method of direct detection of biotin-containing transcripts by streptavidin-Alexa647 conjugate (Molecular Probes, Carlsbad, CA). Processed slides were scanned using a PerkinElmer ScanArray XL5K Scanner, with the laser set to 635 nm, at Power 80 and PMT 70 setting, and a scan resolution of 10 ⁇ m.
- 6X SSPE 0.9 M NaCl/60 mM NaH 2 PO 4 -H 2 O/8 mM EDTA, pH 7.4
- 0.75X TNT Tris-HCl/NaCl/Tween 20
- the expression levels of mature miRNAs were measured by solution hybridization detection using the w/WanaTM miRNA Detection Kit (Ambion Inc., TX). Briefly, 1 ⁇ g total RNA was incubated with radiolabeled probes corresponding to these miRNAs. Following digestion to remove any probe that was not bound by target miRNA, the radiolabeled products were fractionated by denaturing polyacrylamide gel electrophoresis. Probes were prepared by 5' end labeling using T4 Polynucleotide Kinase with /mWanaTM Probe & Marker Kit (Ambion Inc., TX), according to the manufacturer's instructions. Quantitative real-time PCR was performed as described (Schmittgen et al., Nucl.
- RNA was reverse-transcribed to cDNA with gene-specific primers and Thermoscript, and the relative amount of each miRNA to tRNA for initiator methionine was determined, using the equation: 2 "dCT , where dC T (C rm iRNA - C T u ⁇ )- Survival analysis Genes whose expression was significantly related to survival of the patient were identified. A statistical significance level for each gene was computed based on univariate Cox proportional hazard regression model in BRB-ArrayTools version 3.2.3. These p values were then used in a multivariate permutation test in which the survival times and censoring indicators were randomly permuted among arrays. Genes were considered statistically significant if their/? value was less than 0.05.
- the/? value which is defined as the proportion of the random permutations that gave a cross- validated error rate no greater than the cross-validated error rate with the real data, was ⁇ 0.0005.
- hsa-mir-21 and hsa-mir-205 are located at the region amplified in lung cancer, whereas hsa-mir-126* and hsa-mir-126 are at 9q34.3, a region deleted in lung cancer.
- Adeno 13 tumor (65) vs. Adeno norrnal(65) 130 17 0.001 80 ( ⁇ 0.0005)
- Adeno tumor (65) vs. SCC tumor (39) 104 6 0.001 81 ( ⁇ 0.0005) Age classification
- c Amp Amplification
- d Del Deletion
- 6 NSCLC Non-small cell lung carcinoma
- f HCC hepatocellular carcinoma
- ⁇ mlncRNA mRNA-like noncoding RNA
- h ND not defined
- 1 MFHs Malignant fibrous histocytomas.
- Real-time RT-PCR analysis of select precursor miRNAs was performed to validate the results from the microarray analysis.
- cDNA from 16 pairs of lung adenocarcinoma, and 16 pairs of lung squamous cell carcinoma were prepared using gene-specific primers for hsa-mir-21, hsa-mir-126*, hsa-mir-205 and U6 (as a control).
- real-time RT-PCR analyses were performed to determine the expression levels of these miRNAs in the different samples.
- the microarray data for the three precursor miRNAs, hsa-mir-21, hsa-mir-126*, and hsa-mir-205 were confirmed for their mature miRNAs by solution hybridization detection method. Specifically, seven pairs of primary lung cancer tissues and corresponding noncancerous lung tissues, for which sufficient amounts of RNA were available, were analyzed. The mature forms of hsa-mir-21 and hsa-mir-205 were clearly up-regulated in lung cancer tissues when compared with the corresponding noncancerous lung tissues (FIG. T), while hsa-mir-126* was down-regulated in most of the lung cancer tissues examined. Therefore, like the RT-PCR results, these analyses confirmed the microarray expression data for these three miRNAs.
- Example 2 Distinct miRNA expression signatures in human lung cancer cell lines Materials and methods Samples
- SCLCs small cell lung carcinoma
- NSCLCs non-small cell lung carcinoma
- the 5 SCLC cell lines were DMS 92, NCI-H82, NCI-H146, NCI- H446, and NCI-H417 (American Tissue Culture Collection).
- the eight NSCLC cell lines were NCI-H157, CaIu-I, Calu-6, NCI-H292, NCI-H596, A-427, A549, and
- RNA from tissues and cultured cells was isolated by TRIzol ® Reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. Microarray analysis Microarray analysis was performed as previously described (Liu, C.G., et al.,
- Example 3 Identification ofmiRNAs associated with clinicopathological features of lung cancer Materials and methods
- microarray data revealed specific molecular signatures for subsets of lung cancer that differ in clinical behavior was analyzed. For this analysis, the relationship of five types of clinical and pathological information were examined
- Example 4 Correlation between hsa-mir-155 and hsa-let-7a-2 expression and prognosis of patients with lung adenocarcinoma.
- Table 5A Postoperative survival of patients with lung adenocarcinoma in relation to molecular and clinicopathological characteristics and miRNA expression analyzed by microarray analysis.
- Table 5B Postoperative survival of patients with lung adenocarcinoma in relation to clinicopathological characteristics and precursor miRNA expression analyzed by realtime RT-PCR analysis.
- hsa-let-7a showed an over-representation of gene targets linked with protein kinase and intracellular signaling cascades, a finding consistent with the reported functional interaction between let-7 and RAS (Johnson, S.M., et al., Cell 120:635-647 (2005)).
- NLS-bearing substrate-nucleus import GO:0006607 0.000871079 B -c ell differentiation GO:0030183 0.00142995 nucleobase ⁇ micteoside ⁇ nucleotide GO:0006139 0.0021327 and nucleic acid metabolism protein targeting GO:0006605 0.00238267 hemopoiesis GO:0030097 0.00243434 cellular process GO:0009987 0.00270393 uridine metabolism GO:0046108 0.0040568 B-cell activation GO:0042113 0.00458041 h$a-let-7a protein modification GO:0006464 9.02643E-05 cell growth and/or maintenance GO:0008151 9.99217E-05 cellular physiological process GQ:0050875 0.000128316 protein kinase cascade GO:0007243 0.000703203 cellular process GO:0009987 i 0.000870863 intracellular signaling cascade GO-.
- high precursor hsa-mir-155 expression was found to be an independent predictor of poor prognosis by a multivariate Cox proportional hazard regression analysis (Table 5B).
- Table 5B To further confirm whether there was any grouping bias in the original set (32 cases) and the additional set (32 cases), univariate and multivariate survival analyses were performed for all 64 cases.
- Microarray analysis was performed as previously described (Liu, C.G., et aL, Proc. Natl. Acad. ScL U.S.A. 101:9740-9744 (2004), see also, Example 1). Statistical analysis Statistical analyses were performed as described hereinabove (see, e.g.,
- Example 1 5-aza-dC and/or TSA treatment
- A549 and NCI-Hl 57 lung cancer cells (available from the American Tissue Culture Collection) were incubated with medium containing 1.0 ⁇ M 5-aza-dC (Sigma, St. Louis, MO) for 48 hr, then were incubated for an additional 24 hr in the presence of 1.0 ⁇ M TSA (Sigma, St. Louis, MO).
- Total RNA was isolated with TRIzol ® Reagent (Invitrogen), and microarray analysis was performed as described above. Each treatment was performed in triplicate.
- results miRNA microarrays were used to analyze the expression of various miRNAs upon treatment with 5-aza-2'-deoxycytidine (5-aza-dC), a DNA methylation inhibitor, and/or Trichostatin A (TSA), a potent histone deacteylase inhibitor, in two lung cancer cell lines (A549 and NCI-Hl 57).
- 5-aza-2'-deoxycytidine 5-aza-dC
- TSA Trichostatin A
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07717734.3A EP1978986B1 (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods for the diagnosis and prognosis of lung cancer |
AU2007205234A AU2007205234B2 (en) | 2006-01-05 | 2007-01-03 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
ES07717734T ES2429404T3 (en) | 2006-01-05 | 2007-01-03 | MicroRNA-based procedures for the diagnosis and prognosis of lung cancer |
US12/160,034 US7943318B2 (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
JP2008549549A JP5451077B2 (en) | 2006-01-05 | 2007-01-03 | MicroRNA-based methods and compositions for lung cancer diagnosis, prognosis and treatment |
CN2007800067508A CN101400361B (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
CA002633674A CA2633674A1 (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US13/075,828 US8377637B2 (en) | 2006-01-05 | 2011-03-30 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P |
US13/075,820 US8361710B2 (en) | 2006-01-05 | 2011-03-30 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75640006P | 2006-01-05 | 2006-01-05 | |
US60/756,400 | 2006-01-05 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/160,034 A-371-Of-International US7943318B2 (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US13/075,828 Division US8377637B2 (en) | 2006-01-05 | 2011-03-30 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P |
US13/075,820 Division US8361710B2 (en) | 2006-01-05 | 2011-03-30 | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007081720A2 true WO2007081720A2 (en) | 2007-07-19 |
WO2007081720A3 WO2007081720A3 (en) | 2008-02-14 |
Family
ID=38256884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/000103 WO2007081720A2 (en) | 2006-01-05 | 2007-01-03 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
Country Status (8)
Country | Link |
---|---|
US (3) | US7943318B2 (en) |
EP (4) | EP2514433B1 (en) |
JP (1) | JP5451077B2 (en) |
CN (3) | CN103993082B (en) |
AU (1) | AU2007205234B2 (en) |
CA (1) | CA2633674A1 (en) |
ES (4) | ES2553442T3 (en) |
WO (1) | WO2007081720A2 (en) |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009025790A1 (en) * | 2007-08-17 | 2009-02-26 | Catalyst Assets Llc | Diagnostic and prognostic use of human bladder cancer-associated micro rnas |
WO2009024790A1 (en) * | 2007-08-23 | 2009-02-26 | Isis Innovation Limited | Method and kit for the prognosis of cancer by determining the level of mirna-210 |
WO2009044899A1 (en) * | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid capable of regulating the proliferation of cell |
WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
WO2009059016A1 (en) * | 2007-10-30 | 2009-05-07 | Veridex, Llc | Process for predicting the prognosis of squamous cell lung cancer |
JP2009171876A (en) * | 2008-01-23 | 2009-08-06 | Fujifilm Corp | Method for detecting cancer, and cancer inhibitor |
WO2009147658A2 (en) * | 2008-06-02 | 2009-12-10 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
WO2009153775A2 (en) * | 2008-06-17 | 2009-12-23 | Rosetta Genomics Ltd. | Methods for distinguishing between specific types of lung cancers |
WO2009018303A3 (en) * | 2007-07-31 | 2009-12-30 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting dnmt3a and dnmt3b |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
WO2010094155A1 (en) * | 2009-02-23 | 2010-08-26 | Capitalbio Corporation | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
EP2225396A1 (en) * | 2007-11-30 | 2010-09-08 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
ITRM20090136A1 (en) * | 2009-03-24 | 2010-09-25 | Massimo Zollo | USE OF MICRORNA-199B-5P IN MEDICAL AND DIAGNOSTIC FIELD. |
EP2247750A1 (en) * | 2008-02-01 | 2010-11-10 | The Board of Trustees of The Leland Stanford Junior University | Methods and compositions relating to carcinoma stem cells |
EP2300017A2 (en) * | 2008-06-05 | 2011-03-30 | The Research Foundation of State University of New York | Mirnas as therapeutic targets in cancer |
WO2011014083A3 (en) * | 2009-07-30 | 2011-04-07 | Gdański Uniwersytet Medyczny | Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage i-iiia |
WO2011053257A3 (en) * | 2009-11-02 | 2011-08-18 | Agency For Science, Technology And Research (A*Star) | Methods for monitoring cellular states and for immortalizing mesenchymal stem cells |
EP2369012A1 (en) * | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
EP2401405A1 (en) * | 2009-02-26 | 2012-01-04 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
EP2460005A1 (en) * | 2009-07-31 | 2012-06-06 | The Translational Genomics Research Institute | Methods of assessing a risk of cancer progression |
EP2462951A1 (en) * | 2009-07-09 | 2012-06-13 | Cancer Institute, Chinese Academy of Medical Sciences | Use of two microrna moleculars in lung cancer prognosis and medicine preparation |
EP2470897A1 (en) * | 2009-08-28 | 2012-07-04 | Asuragen, Inc. | Mirna biomarkers of lung disease |
WO2012089630A1 (en) | 2010-12-30 | 2012-07-05 | Fondazione Istituto Firc Di Oncologia Molecolare (Ifom) | A METHOD TO IDENTIFY ASYMPTOMATIC HIGH-RISK INDIVIDUALS WITH EARLY STAGE LUNG CANCER BY MEANS OF DETECTING miRNAs IN BIOLOGIC FLUIDS |
CN102559884A (en) * | 2011-12-27 | 2012-07-11 | 芮屈生物技术(上海)有限公司 | LET-7micro ribose nucleic acid (MIRNA) level in-situ hybridization detection kit for pathologic evolution early stage of various cancer, and detection method and application |
ITMI20110174A1 (en) * | 2011-02-07 | 2012-08-08 | Fond Irccs Istituto Nazional E Dei Tumori | PROCEDURE AND EQUIPMENT TO IDENTIFY INDIVIDUALS AT RISK OF PULMONARY AND / OR TO DIAGNOSE A PULMONARY CANCER, AS WELL AS COMPOSITION AND METHOD TO REDUCE OR ELIMINATE THE RISK OF PULMONARY CANCER |
ITMI20110173A1 (en) * | 2011-02-07 | 2012-08-08 | Fond Irccs Istituto Nazional E Dei Tumori | PROCEDURE AND EQUIPMENT TO IDENTIFY INDIVIDUALS AT RISK OF PULMONARY AND / OR TO DIAGNOSE A PULMONARY CANCER, AS WELL AS COMPOSITION AND METHOD TO REDUCE OR ELIMINATE THE RISK OF PULMONARY CANCER |
EP2486929A1 (en) * | 2009-10-01 | 2012-08-15 | National Cancer Center | Therapeutic agent for tumor |
JP2012518421A (en) * | 2009-02-25 | 2012-08-16 | セファイド | How to detect lung cancer |
US8349560B2 (en) | 2007-06-15 | 2013-01-08 | The Ohio State University Research | Method for diagnosing acute lymphomic leukemia (ALL) using miR-222 |
WO2012107841A3 (en) * | 2011-02-07 | 2013-01-17 | Biomirna Holdings Ltd. | Micro -rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof |
CN103080334A (en) * | 2010-06-04 | 2013-05-01 | 复旦大学 | Micro-RNA biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma |
US8440636B2 (en) | 2007-07-31 | 2013-05-14 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
EP2691545A2 (en) * | 2011-03-28 | 2014-02-05 | Rosetta Genomics Ltd | Methods for lung cancer classification |
US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
US8765709B2 (en) | 2004-11-12 | 2014-07-01 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
US8946187B2 (en) | 2010-11-12 | 2015-02-03 | The Ohio State University | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
US9006201B2 (en) | 2010-07-08 | 2015-04-14 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for diabetes |
WO2015056195A1 (en) | 2013-10-15 | 2015-04-23 | Warszawski Uniwersytet Medyczny | Use of microrna markers for diagnosis of liver lesions |
WO2015071876A2 (en) | 2013-11-14 | 2015-05-21 | Warszawski Uniwersytet Medyczny | Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers. |
US9080215B2 (en) | 2007-09-14 | 2015-07-14 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
US9085804B2 (en) | 2007-08-03 | 2015-07-21 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
US9249468B2 (en) | 2011-10-14 | 2016-02-02 | The Ohio State University | Methods and materials related to ovarian cancer |
US9365852B2 (en) | 2008-05-08 | 2016-06-14 | Mirna Therapeutics, Inc. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US9441222B2 (en) | 2011-01-11 | 2016-09-13 | Interna Technologies B.V. | MiRNA for treating diseases and conditions associated with neo-angiogenesis |
US9481885B2 (en) | 2011-12-13 | 2016-11-01 | Ohio State Innovation Foundation | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
US9611478B2 (en) | 2011-02-03 | 2017-04-04 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
CN106755521A (en) * | 2017-02-20 | 2017-05-31 | 南京九寿堂医药科技有限公司 | Blood plasma microRNAs is used for the purposes of the diagnostic reagent for preparing patients with lung adenocarcinoma in sieving and diagnosis female group |
US9682095B2 (en) | 2010-07-06 | 2017-06-20 | Interna Technologies B.V. | MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway |
US9771585B2 (en) | 2015-06-05 | 2017-09-26 | MiRagen Therapeutics, Inc. | miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) |
WO2017194814A1 (en) * | 2016-05-13 | 2017-11-16 | Servicio Andaluz De Salud | Micro-rnas as biomarkers for the diagnosis of lung cancer |
WO2017217935A1 (en) * | 2016-06-14 | 2017-12-21 | Agency For Science, Technology And Research | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
EP3296406A3 (en) * | 2009-06-05 | 2018-05-16 | Hummingbird Diagnostics GmbH | Mirna fingerprint in the diagnosis of lung cancer |
US10047388B2 (en) | 2004-05-28 | 2018-08-14 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
CN109385478A (en) * | 2018-12-20 | 2019-02-26 | 首都医科大学附属北京朝阳医院 | The genetic marker for detecting 19-GCS is preparing the application in the product for diagnosing early stage adenocarcinoma of lung prognosis |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
US10494677B2 (en) | 2006-11-02 | 2019-12-03 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
US10758619B2 (en) | 2010-11-15 | 2020-09-01 | The Ohio State University | Controlled release mucoadhesive systems |
US10865452B2 (en) | 2008-05-28 | 2020-12-15 | Decipher Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
EP3880849A4 (en) * | 2018-11-12 | 2022-08-24 | Mirxes(Hangzhou) Biotechnology Co., Ltd | A peripheral blood mirna marker for diagnosis of non-small cell lung cancer |
US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
US12043872B2 (en) | 2017-06-29 | 2024-07-23 | Toray Industries, Inc. | Kit, device, and method for detecting lung cancer |
US12117462B2 (en) | 2014-06-18 | 2024-10-15 | Toray Industries, Inc. | Lung cancer detection kit or device, and detection method |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
EP1937845B1 (en) | 2005-08-01 | 2015-06-10 | The Ohio State University Research Foundation | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer |
ES2523989T3 (en) | 2005-09-12 | 2014-12-03 | The Ohio State University Research Foundation | Compositions for the therapy of cancers associated with BCL2 |
EP2479285B1 (en) | 2006-01-05 | 2014-05-14 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
EP2586455B1 (en) | 2006-01-05 | 2014-06-25 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
AU2007205234B2 (en) | 2006-01-05 | 2012-07-12 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US8207325B2 (en) * | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
EP2455493B1 (en) | 2006-07-13 | 2014-01-08 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
WO2008097277A2 (en) | 2006-09-19 | 2008-08-14 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
EP2487240B1 (en) * | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
JP5501766B2 (en) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA expression signature to predict survival and metastasis in hepatocellular carcinoma |
CA2674895A1 (en) | 2007-01-31 | 2008-08-07 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml) |
EP2481805A3 (en) * | 2007-04-30 | 2012-10-24 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
CN101711287B (en) | 2007-06-08 | 2016-04-27 | 由卫生与公众服务部代表的美利坚合众国政府 | Determine the method for hepatocellular carcinoma hypotype and detection liver-cancer stem cell |
JP5770472B2 (en) | 2007-08-22 | 2015-08-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemia |
JP5723156B2 (en) * | 2007-10-11 | 2015-05-27 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | Methods and compositions for diagnosis and treatment of esophageal adenocarcinoma |
WO2009055773A2 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
EP2257647B1 (en) * | 2008-02-28 | 2016-09-14 | The Ohio State University Research Foundation | Micro rna-based methods and compositions for the diagnosis of gastric cancer |
EP2307028B1 (en) | 2008-06-11 | 2013-10-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
EP2358912B1 (en) * | 2008-10-30 | 2016-10-12 | Caris Life Sciences Switzerland Holdings GmbH | Methods for assessing rna patterns |
GB2463401B (en) * | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
CN101475984A (en) * | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | Non-small cell lung cancer detection marker, detection method thereof, related biochip and reagent kit |
US20100240049A1 (en) | 2009-01-16 | 2010-09-23 | Cepheid | Methods of Detecting Cervical Cancer |
JP2012515532A (en) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ, リミテッド | MIR-21 promoter driven target cancer treatment |
WO2010093907A2 (en) * | 2009-02-13 | 2010-08-19 | The Board Of Regents Of The University Of Texas System | An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1 |
JP2012522508A (en) | 2009-03-31 | 2012-09-27 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Differentially expressed microRNA as a biomarker for diagnosis and treatment of Sjogren's syndrome |
US20110105585A1 (en) * | 2009-04-23 | 2011-05-05 | Northwestern University | METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF |
CN102018963B (en) * | 2009-09-11 | 2013-03-13 | 中国科学院上海生命科学研究院 | MiR-125a for adjusting regulated on activation normal T cell expressed and secreted (RANTES) expressions as well as composition and application thereof |
CN102080083B (en) * | 2009-12-01 | 2013-02-27 | 中国科学院上海药物研究所 | Human miR-149 antisense nucleotide and application thereof |
WO2011084815A1 (en) * | 2009-12-21 | 2011-07-14 | Board Of Trustees Of Southern Illinois University | Inhibition of ubc9-mediated cancer cell invasion and metastasis |
WO2011076145A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer |
CN102782155B (en) * | 2009-12-24 | 2016-05-04 | 复旦大学 | Be used for composition and the method for the blood plasma micro-RNA expression analysis of spectrum of lung cancer |
CN102770561B (en) * | 2009-12-24 | 2015-05-06 | 复旦大学 | Tissue-based micro-RNA methods for diagnosis of different subtypes of lung cancer |
KR20130056855A (en) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Biomarkers for theranostics |
WO2011115884A1 (en) * | 2010-03-18 | 2011-09-22 | Centocor Ortho Biotech Inc. | Diagnostic for lung cancer using mirna |
WO2011119553A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
JPWO2011125245A1 (en) * | 2010-04-05 | 2013-07-08 | 公益財団法人がん研究会 | Method for predicting prognosis of small cell lung cancer using miRNA, method for treating small cell lung cancer, method for improving prognosis of small cell lung cancer, and method for screening agent for treating small cell lung cancer |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
WO2011156777A1 (en) | 2010-06-10 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Use of blood mir-210 for cancer prognosis |
CN102140466B (en) * | 2010-12-30 | 2013-03-27 | 苏州吉玛基因股份有限公司 | Human miR-1825 antisense nucleic acid and application thereof |
CN102140467B (en) * | 2010-12-30 | 2013-05-15 | 苏州吉玛基因股份有限公司 | Human miR-365 antisense nucleic acid and application thereof |
WO2012097047A1 (en) * | 2011-01-11 | 2012-07-19 | The Ohio State University Research Foundation | Methods to identify chronic lymphocytic leukemia disease progression |
CN102586412B (en) * | 2011-01-18 | 2015-05-20 | 上海市第一人民医院 | MicroRNA (ribonucleic acid) specific expression profile and application thereof |
EP2668295A4 (en) | 2011-01-26 | 2016-01-13 | Cepheid | Methods of detecting lung cancer |
CN102533983A (en) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA-330 in earlier stage of cancer pathologic evolution |
CN102533984A (en) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA17-3P in earlier stage of cancer pathologic evolution |
ITRM20110685A1 (en) | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | MICRORNA FOR CARDIAC REGENERATION THROUGH THE INDUCTION OF THE PROLIFERATION OF CARDIAC MYCYCLES |
CN102776194A (en) * | 2012-07-20 | 2012-11-14 | 苏州大学 | MicroRNA (micro ribonucleic acid) for regulating gene expression of PTEN (phosphatase and tensin homolog) |
US10196662B2 (en) * | 2012-08-10 | 2019-02-05 | Mello Biotechnology, Inc. | Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors |
KR101501826B1 (en) * | 2013-04-05 | 2015-03-13 | 연세대학교 산학협력단 | Method for preparing prognosis prediction model of gastric cancer |
CN103285406B (en) * | 2013-05-27 | 2015-05-13 | 哈尔滨医科大学 | MicroRNA-203, and application of analogue thereof in preparation of medicament for preventing and treating obesity, dyslipidemia and complication of obesity and dyslipidemia |
CN103751801A (en) * | 2013-09-10 | 2014-04-30 | 上海大学 | Application of miR-143 gene in non-small-cell lung carcinoma |
CN103948926A (en) * | 2014-03-24 | 2014-07-30 | 江苏大学 | Use of miR-9 inhibitor in preparation of tumor growth inhibition drugs |
CN104031987B (en) * | 2014-05-12 | 2016-08-31 | 贵州省人民医院 | MiRNA application in myocardial fibrosis disease treatment |
CN104152452B (en) * | 2014-08-19 | 2016-08-24 | 中国人民解放军总医院第一附属医院 | A kind of blood miRNA marker relevant to hepatocarcinoma and application thereof |
US20160070852A1 (en) * | 2014-09-04 | 2016-03-10 | National Taiwan University | Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method |
CN104911248A (en) * | 2014-12-18 | 2015-09-16 | 南京大学 | Micro RNA combination used for II and III stage colorectal cancer diagnosis and prognosis as well as application thereof |
CN104726448B (en) * | 2014-12-29 | 2018-03-30 | 常州杰傲病理诊断技术有限公司 | A kind of miRNA marker and application for cancerous lung tissue parting |
MX2017014859A (en) * | 2015-05-19 | 2018-07-06 | Wistar Inst | Methods and compositions for diagnosing or detecting lung cancers. |
CN105457041B (en) * | 2015-12-09 | 2020-09-08 | 上海大学 | Application of miR-26a in non-small cell lung cancer |
CN105561339B (en) * | 2015-12-21 | 2019-02-22 | 江苏省人民医院 | A kind of combination of miRNA prepares the application in anti-non-small cell lung cancer drug |
CN105726559B (en) * | 2016-03-21 | 2018-12-18 | 南通大学 | MiRNA-17-3p and miRNA-19b-1 composition and its application |
CN109563510A (en) * | 2016-05-27 | 2019-04-02 | 林希龙 | MIR-302 presoma is used to be used to treat the composition and method of Human Lung Cancer as anticancer drug |
CN106055921A (en) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | Pharmaceutical activity prediction and selection method based on genetic expressions and drug targets |
CN105950753B (en) * | 2016-06-16 | 2019-10-01 | 朱伟 | One kind blood plasma miRNA marker relevant to adenocarcinoma of lung auxiliary diagnosis and its application |
KR101888744B1 (en) | 2016-08-02 | 2018-10-04 | 연세대학교 산학협력단 | Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors |
US10738363B2 (en) | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
JP7130639B2 (en) | 2016-11-01 | 2022-09-05 | ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク | 5-Halouracil-Modified MicroRNAs and Their Use in Treating Cancer |
WO2018096060A1 (en) * | 2016-11-25 | 2018-05-31 | Centre National De La Recherche Scientifique | Agents for the treatment of patients with nsclc and methods to predict response |
CN107058480B (en) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院(河北省肿瘤医院) | Long-chain non-coding RNA marker for diagnosing adenocarcinoma of lung |
US10314855B2 (en) | 2017-01-23 | 2019-06-11 | Trustees Of Boston University | Methods relating to lung cancer |
CN113604564A (en) * | 2017-08-14 | 2021-11-05 | 江苏为真生物医药技术股份有限公司 | Method for detecting exosome-associated microRNA (ribonucleic acid) molecules |
CN107475388B (en) * | 2017-08-22 | 2020-05-19 | 深圳市恩普电子技术有限公司 | Application of nasopharyngeal carcinoma related miRNA as biomarker and nasopharyngeal carcinoma detection kit |
CN108096266A (en) * | 2017-11-30 | 2018-06-01 | 佛山英特医药科技有限公司 | MiRNA-370 is in antitumor action, implementation and purposes |
CN108841962B (en) * | 2018-08-01 | 2021-11-19 | 博奥生物集团有限公司 | Non-small cell lung cancer detection kit and application thereof |
JP2020092688A (en) * | 2018-12-12 | 2020-06-18 | 国立大学法人東海国立大学機構 | Body fluid extract containing micro rna |
CN111218513B (en) * | 2020-04-24 | 2020-08-14 | 上海思路迪医学检验所有限公司 | Peripheral blood extracellular vesicle microRNA biomarker for early diagnosis of lung cancer and application thereof |
JPWO2023074135A1 (en) * | 2021-11-01 | 2023-05-04 | ||
CN116585342B (en) * | 2023-05-23 | 2024-08-16 | 源生生物科技(青岛)有限责任公司 | Active ingredient containing miRNA and application thereof |
CN117286252B (en) * | 2023-11-16 | 2024-04-09 | 上海交通大学医学院 | Biomarker combination for diagnosing and prognosis evaluating lung cancer and application thereof |
CN118236389B (en) * | 2024-05-28 | 2024-09-24 | 南京晖丽生物科技有限公司 | Application of miR-3120 in preparation of pharmaceutical composition for preventing and treating tumor and tumor cachexia |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
WO1993024641A2 (en) | 1992-06-02 | 1993-12-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Adeno-associated virus with inverted terminal repeat sequences as promoter |
WO1994013788A1 (en) | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
US5427916A (en) | 1988-05-09 | 1995-06-27 | Temple University Of The Commonwealth System Of Higher Education | Method for predicting the effectiveness of antineoplastic therapy in individual patients |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US20020086356A1 (en) | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
US20040014113A1 (en) | 2002-05-31 | 2004-01-22 | The Regents Of The University Of California | Method for efficient RNA interference in mammalian cells |
US20040018176A1 (en) | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
WO2005118806A2 (en) | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4608337A (en) | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
US4701409A (en) | 1984-11-15 | 1987-10-20 | The Wistar Institute | Detection of B-cell neoplasms |
US4693975A (en) | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4712124A (en) * | 1986-12-22 | 1987-12-08 | North American Philips Corporation | Complementary lateral insulated gate rectifiers with matched "on" resistances |
US5198338A (en) | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
US5149628A (en) | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
US6040140A (en) | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
US5633135A (en) | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
WO1993012136A1 (en) | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
CA2148350A1 (en) | 1992-10-29 | 1994-05-11 | Carlo Croce | Methods of detecting micrometastasis of prostate cancer |
US5985598A (en) | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
US7175995B1 (en) | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
US5695944A (en) | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
US5567586A (en) | 1995-05-18 | 1996-10-22 | Thomas Jefferson University | Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region |
US5928884A (en) | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
WO1998035707A1 (en) | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
EP0972083A1 (en) | 1997-04-04 | 2000-01-19 | THE TEXAS A&M UNIVERSITY SYSTEM | Noninvasive detection of colonic biomarkers using fecal messenger rna |
CA2335315A1 (en) | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
US6255293B1 (en) | 1998-07-24 | 2001-07-03 | Yeda Research And Development Co., Ltd. | Prevention of metastasis with 5-aza-2′-deoxycytidine |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
CA2367906A1 (en) | 1999-03-15 | 2000-09-21 | Thomas Jefferson University | Tcl-1b gene and protein and related methods and compositions |
US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
SE0000522D0 (en) * | 2000-02-17 | 2000-02-17 | Astrazeneca Ab | Mixing apparatus |
US6891031B2 (en) | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
WO2001068666A1 (en) | 2000-03-14 | 2001-09-20 | Thomas Jefferson University | Tcl1 enhances akt kinase activity and mediates its nuclear translocation |
EP1276879A4 (en) | 2000-04-11 | 2004-12-22 | Univ Jefferson | MUIR-TORRE-LIKE SYNDROME IN Fhit DEFICIENT MICE |
US20020086331A1 (en) | 2000-05-16 | 2002-07-04 | Carlo Croce | Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers |
US7060811B2 (en) | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
US20040033502A1 (en) | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
EP1430128B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
GB0128898D0 (en) | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
WO2003076424A1 (en) | 2002-03-08 | 2003-09-18 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
US20060084059A1 (en) | 2002-04-08 | 2006-04-20 | Tai-Tung Yip | Serum biomarkers in hepatocellular carcinoma |
US20040078834A1 (en) | 2002-04-29 | 2004-04-22 | Croce Carlo M. | Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression |
EP1530418A4 (en) | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | Methods of identifying and isolating stem cells and cancer stem cells |
WO2004005891A2 (en) * | 2002-07-10 | 2004-01-15 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
EP1581621A4 (en) | 2002-10-11 | 2006-07-05 | Univ Jefferson | Novel tumor suppressor gene and compositions and methods for making and using the same |
JP4939055B2 (en) * | 2002-11-13 | 2012-05-23 | トマス ジェファソン ユニバーシティ | Compositions and methods for diagnosis and treatment of cancer |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004071464A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
US7183384B2 (en) | 2003-03-06 | 2007-02-27 | A & G Pharmaceutical, Inc. | Monoclonal antibody 7H11 reactive with human cancer |
AU2003286741A1 (en) | 2003-05-02 | 2004-11-26 | Thomas Jefferson University | Methods and compositions for diagnosis and therapy of parkin-associated disorders |
US20050069918A1 (en) | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
AU2004289953B2 (en) | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
US20050037362A1 (en) | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
US8412541B2 (en) | 2003-08-14 | 2013-04-02 | Edda Technology, Inc. | Method and system for intelligent qualitative and quantitative analysis for medical diagnosis |
US20050084883A1 (en) | 2003-08-25 | 2005-04-21 | The Johns Hopkins University School Of Medicine | Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis |
JP2007505634A (en) | 2003-09-22 | 2007-03-15 | ロゼッタ インファーマティクス エルエルシー | Synthetic lethal screening using RNA interference |
EP1668155A2 (en) | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc) |
US20050186589A1 (en) | 2003-11-07 | 2005-08-25 | University Of Massachusetts | Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi |
US20050164252A1 (en) | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
ATE502298T1 (en) | 2003-12-19 | 2011-04-15 | Univ California | METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES |
US20050256072A1 (en) * | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
CA2556435C (en) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
SG155968A1 (en) | 2004-02-23 | 2009-10-29 | Univ Erasmus Medical Ct | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
KR20070004957A (en) | 2004-04-20 | 2007-01-09 | 제나코 바이오메디컬 프로덕츠, 인코포레이티드 | Method for detecting ncrna |
EP1784501B1 (en) | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
US20060037088A1 (en) | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
CA2583375C (en) | 2004-09-02 | 2013-01-15 | Yale University | Regulation of oncogenes by micrornas |
US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
FR2877350B1 (en) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA |
ES2534304T3 (en) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedures and compositions involving miRNA and miRNA inhibitor molecules |
CA2590768A1 (en) | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
EP1851336B1 (en) | 2005-01-25 | 2010-09-08 | Rosetta Inpharmatics LLC | Methods for quantitating small rna molecules |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
GB2425311A (en) | 2005-04-15 | 2006-10-25 | Ist Superiore Sanita | Micro RNA against kit protein |
AU2006242225B2 (en) | 2005-04-29 | 2012-01-12 | Rockefeller University | Human microRNAs and methods for inhibiting same |
EP1904111A4 (en) | 2005-06-03 | 2009-08-19 | Univ Johns Hopkins | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
US20070065844A1 (en) | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
EP1937845B1 (en) | 2005-08-01 | 2015-06-10 | The Ohio State University Research Foundation | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20070123482A1 (en) | 2005-08-10 | 2007-05-31 | Markus Stoffel | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
ES2523989T3 (en) | 2005-09-12 | 2014-12-03 | The Ohio State University Research Foundation | Compositions for the therapy of cancers associated with BCL2 |
EP1940456A4 (en) | 2005-10-05 | 2009-10-21 | Univ Ohio State Res Found | Wwox gene, vectors containing the same, and uses in treatment of cancer |
US7390792B2 (en) | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
EP2586455B1 (en) | 2006-01-05 | 2014-06-25 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP2479285B1 (en) | 2006-01-05 | 2014-05-14 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
AU2007205234B2 (en) | 2006-01-05 | 2012-07-12 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US20090007281A1 (en) | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
MX2008012219A (en) | 2006-04-03 | 2008-10-02 | Santaris Pharma As | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides. |
US7667090B2 (en) | 2006-04-24 | 2010-02-23 | The Ohio State University Research Foundation | Transgenic mouse model of B cell malignancy |
EP2455493B1 (en) | 2006-07-13 | 2014-01-08 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
US20080193943A1 (en) | 2006-09-05 | 2008-08-14 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
JP2010504350A (en) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | Genes and pathways regulated by miR-200 as targets for therapeutic intervention |
WO2008097277A2 (en) | 2006-09-19 | 2008-08-14 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
JP5501766B2 (en) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA expression signature to predict survival and metastasis in hepatocellular carcinoma |
US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
WO2008070082A2 (en) | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
EP2104735A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
EP2104734A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
CA2671299A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
US20090092974A1 (en) | 2006-12-08 | 2009-04-09 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
US20090175827A1 (en) | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
CA2674895A1 (en) | 2007-01-31 | 2008-08-07 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml) |
KR20100027102A (en) | 2007-04-10 | 2010-03-10 | 내셔널 타이완 유니버시티 | Predicting post-treatment survival in cancer patients with micrornas |
EP2481805A3 (en) | 2007-04-30 | 2012-10-24 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
US20090005336A1 (en) | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
US20090232893A1 (en) | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
CN101711287B (en) | 2007-06-08 | 2016-04-27 | 由卫生与公众服务部代表的美利坚合众国政府 | Determine the method for hepatocellular carcinoma hypotype and detection liver-cancer stem cell |
CA2689974A1 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
CN101918424A (en) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
CN101809169B (en) | 2007-07-31 | 2013-07-17 | 俄亥俄州立大学研究基金会 | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
EP2653561B1 (en) | 2007-08-03 | 2016-03-02 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
JP5770472B2 (en) | 2007-08-22 | 2015-08-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemia |
US20090061424A1 (en) | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
EP3048177A1 (en) | 2007-09-06 | 2016-07-27 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
JP5723156B2 (en) | 2007-10-11 | 2015-05-27 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | Methods and compositions for diagnosis and treatment of esophageal adenocarcinoma |
WO2009055773A2 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
US20090123933A1 (en) | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
US8575121B2 (en) | 2007-11-12 | 2013-11-05 | The United States of America as represented by the Secetary of the Department of Health and Human Services | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
EP2225396A4 (en) | 2007-11-30 | 2011-03-02 | Univ Ohio State Res Found | Microrna expression profiling and targeting in peripheral blood in lung cancer |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
SG10201609507TA (en) | 2008-02-01 | 2017-01-27 | Gen Hospital Corp | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
US20110021609A1 (en) | 2008-02-28 | 2011-01-27 | The Ohio State University Research Foundation | MicroRNA Signatures Associated with Cytogenetics and Prognosis in Acute Myeloid Leukemia (AML) and Uses Thereof |
CA2717026A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
EP2257647B1 (en) | 2008-02-28 | 2016-09-14 | The Ohio State University Research Foundation | Micro rna-based methods and compositions for the diagnosis of gastric cancer |
JP2011517283A (en) | 2008-02-28 | 2011-06-02 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA-based methods and compositions for prognosis and treatment of prostate related disorders |
WO2009111643A2 (en) | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
EP2271757A2 (en) | 2008-03-26 | 2011-01-12 | Asuragen, INC. | Compositions and methods related to mir-16 and therapy of prostate cancer |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
CN102112110A (en) | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | Novel compositions for the in vivo delivery of RNAi agents |
EP2307028B1 (en) | 2008-06-11 | 2013-10-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
US20110152357A1 (en) | 2008-08-12 | 2011-06-23 | The Ohio State University | Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma |
CN102271706A (en) | 2008-11-21 | 2011-12-07 | 俄亥俄州立大学研究基金会 | Tcl1 as a transcriptional regulator |
WO2010065156A1 (en) | 2008-12-05 | 2010-06-10 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer |
EP2401405A4 (en) | 2009-02-26 | 2013-10-16 | Univ Ohio State Res Found | Micrornas in never-smokers and related materials and methods |
-
2007
- 2007-01-03 AU AU2007205234A patent/AU2007205234B2/en not_active Ceased
- 2007-01-03 CN CN201410210166.6A patent/CN103993082B/en not_active Expired - Fee Related
- 2007-01-03 WO PCT/US2007/000103 patent/WO2007081720A2/en active Application Filing
- 2007-01-03 CN CN201210312507.1A patent/CN102943108B/en not_active Expired - Fee Related
- 2007-01-03 EP EP12165734.0A patent/EP2514433B1/en not_active Not-in-force
- 2007-01-03 JP JP2008549549A patent/JP5451077B2/en not_active Expired - Fee Related
- 2007-01-03 ES ES12165740.7T patent/ES2553442T3/en active Active
- 2007-01-03 EP EP07717734.3A patent/EP1978986B1/en not_active Not-in-force
- 2007-01-03 EP EP12165740.7A patent/EP2514434B1/en not_active Not-in-force
- 2007-01-03 ES ES12165748.0T patent/ES2536438T3/en active Active
- 2007-01-03 CN CN2007800067508A patent/CN101400361B/en not_active Expired - Fee Related
- 2007-01-03 ES ES07717734T patent/ES2429404T3/en active Active
- 2007-01-03 EP EP12165748.0A patent/EP2502630B1/en not_active Not-in-force
- 2007-01-03 CA CA002633674A patent/CA2633674A1/en not_active Abandoned
- 2007-01-03 ES ES12165734.0T patent/ES2554531T3/en active Active
- 2007-01-03 US US12/160,034 patent/US7943318B2/en active Active
-
2011
- 2011-03-30 US US13/075,820 patent/US8361710B2/en not_active Expired - Fee Related
- 2011-03-30 US US13/075,828 patent/US8377637B2/en not_active Expired - Fee Related
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5427916A (en) | 1988-05-09 | 1995-06-27 | Temple University Of The Commonwealth System Of Higher Education | Method for predicting the effectiveness of antineoplastic therapy in individual patients |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
WO1993024641A2 (en) | 1992-06-02 | 1993-12-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Adeno-associated virus with inverted terminal repeat sequences as promoter |
WO1994013788A1 (en) | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US20020086356A1 (en) | 2000-03-30 | 2002-07-04 | Whitehead Institute For Biomedical Research | RNA sequence-specific mediators of RNA interference |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
US20040014113A1 (en) | 2002-05-31 | 2004-01-22 | The Regents Of The University Of California | Method for efficient RNA interference in mammalian cells |
US20040018176A1 (en) | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
WO2005118806A2 (en) | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
Non-Patent Citations (38)
Title |
---|
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Remington's Pharmaceutical Science", 1985, MACK PUBLISHING COMPANY |
ANDERSON, NATURE, vol. 392, 1998, pages 25 - 30 |
BRUMMELKAMP ET AL., SCIENCE, vol. 296, 2002, pages 550 - 553 |
CALIN, G.A. ET AL., PROC. NATL. ACAD. SCI. US.A., vol. 99, 2002, pages 15524 - 15529 |
CALIN, G.A. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 101, 2004, pages 1175 - 11760 |
CARBONE, J CLIN. ONCOL., vol. 23, 2005, pages 3219 - 3226 |
CHENG, A.M. ET AL., NUCLEIC ACIDS RES., vol. 33, 2005, pages 1290 - 1297 |
DORNBURG, GENE THERAP., vol. 2, 1995, pages 301 - 310 |
EGLITIS, BIOTECHNIQUES, vol. 6, 1988, pages 608 - 614 |
FIENBERG ET AL., ANAL. BIOCHEM., vol. 132, 1983, pages 6 - 13 |
FISHER ET AL., J VIRAL., vol. 70, 1996, pages 520 - 532 |
GABIZON ET AL., PROC. NATL. ACAD. SCI., U.S.A., vol. 18, 1988, pages 6949 - 53 |
GRANVILLE, DENNIS, CELL MOL. BIOL., vol. 32, 2005, pages 169 - 176 |
HAMMANN ET AL., ANTISENSE AND NUCLEIC ACID DRUG DEV., vol. 9, 1999, pages 25 - 31 |
ISHIZUKA, A. ET AL., GENES DEV., vol. 16, 2002, pages 2497 - 2508 |
JOHNSON S.M. ET AL., CELL, vol. 120, 11 March 2005 (2005-03-11), pages 635 - 647 |
LEE ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 500 - 505 |
LIU, C. G. ET AL., PROC NATL. ACAD. SCI. US.A., vol. 101, 2004, pages 9740 - 9744 |
MILLER, HUM. GENE THERAP., vol. 1, 1990, pages 5 - 14 |
MINNA ET AL., CANCER CELL, vol. 1, 2002, pages 49 - 52 |
MIYAGISHI ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 497 - 500 |
PADDISON ET AL., GENES DEV., vol. 16, 2002, pages 948 - 958 |
PAUL ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 505 - 508 |
RABINOWITZ, J.E. ET AL., J VROL., vol. 76, 2002, pages 791 - 801 |
RIGBY ET AL., J MOL. BIOL., vol. 113, 1977, pages 237 - 251 |
SAMULSKI ET AL., J VIROL., vol. 61, 1987, pages 3096 - 3101 |
SAMULSKI ET AL., J VIROL., vol. 63, 1989, pages 3822 - 3826 |
See also references of EP1978986A4 |
SEKIDO, ANNU. REV. MED., vol. 54, 2003, pages 73 - 87 |
STEIN, CHENG, SCIENCE, vol. 261, 1993, pages 1004 |
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467 |
TAKAMIZAWA J. ET AL., CANCER RESEARCH, vol. 64, 1 June 2004 (2004-06-01), pages 3753 - 3756 |
TUSCHL, NAT. BIOTECHNOL, vol. 20, 2002, pages 446 - 448 |
WERNER, UHLENBECK, NUCL. ACIDS RES., vol. 23, 1995, pages 2092 - 96 |
XIA ET AL., NAT. BIOTECH., vol. 20, 2002, pages 1006 - 1010 |
YOKOTA, KOHNO, CANCER SCI., vol. 95, 2004, pages 197 - 204 |
ZENG ET AL., MOLECULAR CELL, vol. 9, 2002, pages 1327 - 1333 |
Cited By (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10047388B2 (en) | 2004-05-28 | 2018-08-14 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
US9068219B2 (en) | 2004-11-12 | 2015-06-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9051571B2 (en) | 2004-11-12 | 2015-06-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9506061B2 (en) | 2004-11-12 | 2016-11-29 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9382537B2 (en) | 2004-11-12 | 2016-07-05 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US9447414B2 (en) | 2004-11-12 | 2016-09-20 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
US8765709B2 (en) | 2004-11-12 | 2014-07-01 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP2369012A1 (en) * | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
US10494677B2 (en) | 2006-11-02 | 2019-12-03 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
US8349560B2 (en) | 2007-06-15 | 2013-01-08 | The Ohio State University Research | Method for diagnosing acute lymphomic leukemia (ALL) using miR-222 |
CN101809169A (en) * | 2007-07-31 | 2010-08-18 | 俄亥俄州立大学研究基金会 | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
US9719086B2 (en) | 2007-07-31 | 2017-08-01 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
WO2009018303A3 (en) * | 2007-07-31 | 2009-12-30 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting dnmt3a and dnmt3b |
AU2008282318B2 (en) * | 2007-07-31 | 2014-02-27 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting methyltransferases |
US8440636B2 (en) | 2007-07-31 | 2013-05-14 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
US9719087B2 (en) | 2007-07-31 | 2017-08-01 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
CN101809169B (en) * | 2007-07-31 | 2013-07-17 | 俄亥俄州立大学研究基金会 | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
US8940713B2 (en) | 2007-07-31 | 2015-01-27 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
US8940712B2 (en) | 2007-07-31 | 2015-01-27 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
US8940711B2 (en) | 2007-07-31 | 2015-01-27 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
JP2010535782A (en) * | 2007-07-31 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | Method for reversing methylation by targeting DNMT3A and DNMT3B |
US9719088B2 (en) | 2007-07-31 | 2017-08-01 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
EP2808398A1 (en) * | 2007-07-31 | 2014-12-03 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
US10392618B2 (en) | 2007-07-31 | 2019-08-27 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates extracellular matrix genes and uses thereof |
US9085804B2 (en) | 2007-08-03 | 2015-07-21 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
WO2009025790A1 (en) * | 2007-08-17 | 2009-02-26 | Catalyst Assets Llc | Diagnostic and prognostic use of human bladder cancer-associated micro rnas |
WO2009024790A1 (en) * | 2007-08-23 | 2009-02-26 | Isis Innovation Limited | Method and kit for the prognosis of cancer by determining the level of mirna-210 |
US9080215B2 (en) | 2007-09-14 | 2015-07-14 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
WO2009044899A1 (en) * | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid capable of regulating the proliferation of cell |
WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
US7927805B2 (en) | 2007-10-30 | 2011-04-19 | Veridex, Llc | Process for predicting the prognosis of squamous cell lung cancer |
WO2009059016A1 (en) * | 2007-10-30 | 2009-05-07 | Veridex, Llc | Process for predicting the prognosis of squamous cell lung cancer |
EP2225396A4 (en) * | 2007-11-30 | 2011-03-02 | Univ Ohio State Res Found | Microrna expression profiling and targeting in peripheral blood in lung cancer |
EP2225396A1 (en) * | 2007-11-30 | 2010-09-08 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
CN101918594A (en) * | 2007-11-30 | 2010-12-15 | 俄亥俄州立大学研究基金会 | Micro-RNA expression profiling and targeting in peripheral blood in lung cancer |
US8183223B2 (en) | 2008-01-23 | 2012-05-22 | Fujifilm Corporation | Method for detecting carcinoma and agent for suppressing carcinoma |
EP2088208A1 (en) | 2008-01-23 | 2009-08-12 | Fujifilm Corporation | Method for detecting carcinoma and agent for suppressing carcinoma |
JP2009171876A (en) * | 2008-01-23 | 2009-08-06 | Fujifilm Corp | Method for detecting cancer, and cancer inhibitor |
JP2011511634A (en) * | 2008-02-01 | 2011-04-14 | ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ | Methods and compositions relating to cancer stem cells |
CN101981206A (en) * | 2008-02-01 | 2011-02-23 | 利兰·斯坦福青年大学托管委员会 | Methods and compositions relating to carcinoma stem cells |
EP2247750A1 (en) * | 2008-02-01 | 2010-11-10 | The Board of Trustees of The Leland Stanford Junior University | Methods and compositions relating to carcinoma stem cells |
EP2247750A4 (en) * | 2008-02-01 | 2011-10-26 | Univ Leland Stanford Junior | Methods and compositions relating to carcinoma stem cells |
US9365852B2 (en) | 2008-05-08 | 2016-06-14 | Mirna Therapeutics, Inc. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US10865452B2 (en) | 2008-05-28 | 2020-12-15 | Decipher Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
WO2009147658A3 (en) * | 2008-06-02 | 2010-01-28 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
WO2009147658A2 (en) * | 2008-06-02 | 2009-12-10 | New York University | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
EP2300017A2 (en) * | 2008-06-05 | 2011-03-30 | The Research Foundation of State University of New York | Mirnas as therapeutic targets in cancer |
EP2300017A4 (en) * | 2008-06-05 | 2012-12-12 | Univ New York State Res Found | Mirnas as therapeutic targets in cancer |
WO2009153775A2 (en) * | 2008-06-17 | 2009-12-23 | Rosetta Genomics Ltd. | Methods for distinguishing between specific types of lung cancers |
WO2009153775A3 (en) * | 2008-06-17 | 2010-03-18 | Rosetta Genomics Ltd. | Methods for distinguishing between specific types of lung cancers |
WO2010007093A1 (en) * | 2008-07-17 | 2010-01-21 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
WO2010094155A1 (en) * | 2009-02-23 | 2010-08-26 | Capitalbio Corporation | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
JP2012518421A (en) * | 2009-02-25 | 2012-08-16 | セファイド | How to detect lung cancer |
EP2401405A1 (en) * | 2009-02-26 | 2012-01-04 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
EP2401405A4 (en) * | 2009-02-26 | 2013-10-16 | Univ Ohio State Res Found | Micrornas in never-smokers and related materials and methods |
ITRM20090136A1 (en) * | 2009-03-24 | 2010-09-25 | Massimo Zollo | USE OF MICRORNA-199B-5P IN MEDICAL AND DIAGNOSTIC FIELD. |
JP2015144603A (en) * | 2009-03-24 | 2015-08-13 | アドヴァンスド・アクセラレーター・アプリケーションズ | Use of microrna-199b-5 p in medical and diagnostic fields |
JP2012521213A (en) * | 2009-03-24 | 2012-09-13 | アドヴァンスド・アクセラレーター・アプリケーションズ | Use of microRNA-199B-5P in the medical and diagnostic fields |
CN102482669A (en) * | 2009-03-24 | 2012-05-30 | 先进加速器申请公司 | Use of microrna-199b-5p in medical and diagnostic field |
US9017938B2 (en) | 2009-03-24 | 2015-04-28 | Advanced Accelerator Applications | Use of microrna-199b-5p in medical and diagnostic field |
WO2010109511A1 (en) * | 2009-03-24 | 2010-09-30 | Massimo Zollo | Use of microrna-199b-5p in medical and diagnostic field |
AU2010228856B2 (en) * | 2009-03-24 | 2015-04-09 | Advanced Accelerator Applications | Use of MicroRNA-199b-5p in medical and diagnostic field |
EP3296406A3 (en) * | 2009-06-05 | 2018-05-16 | Hummingbird Diagnostics GmbH | Mirna fingerprint in the diagnosis of lung cancer |
EP2462951A4 (en) * | 2009-07-09 | 2013-01-09 | Cancer Inst Cams | Use of two microrna moleculars in lung cancer prognosis and medicine preparation |
JP2012532149A (en) * | 2009-07-09 | 2012-12-13 | 中国医学科学院▲腫▼瘤研究所 | Use of two microRNAs in lung cancer prognosis and drug preparation |
EP2462951A1 (en) * | 2009-07-09 | 2012-06-13 | Cancer Institute, Chinese Academy of Medical Sciences | Use of two microrna moleculars in lung cancer prognosis and medicine preparation |
EP3037550A1 (en) * | 2009-07-30 | 2016-06-29 | Marcin Skrzypski | Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage i-iiia |
WO2011014083A3 (en) * | 2009-07-30 | 2011-04-07 | Gdański Uniwersytet Medyczny | Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage i-iiia |
US8911940B2 (en) | 2009-07-31 | 2014-12-16 | The Translational Genomics Research Institute | Methods of assessing a risk of cancer progression |
EP2460005A1 (en) * | 2009-07-31 | 2012-06-06 | The Translational Genomics Research Institute | Methods of assessing a risk of cancer progression |
EP2460005A4 (en) * | 2009-07-31 | 2012-11-21 | Translational Genomics Res Inst | Methods of assessing a risk of cancer progression |
EP2470897A4 (en) * | 2009-08-28 | 2013-05-29 | Asuragen Inc | Mirna biomarkers of lung disease |
EP2775300A3 (en) * | 2009-08-28 | 2015-04-01 | Asuragen, INC. | miRNA Biomarkers of Lung Disease |
EP2470897A1 (en) * | 2009-08-28 | 2012-07-04 | Asuragen, Inc. | Mirna biomarkers of lung disease |
US8735074B2 (en) | 2009-08-28 | 2014-05-27 | Asuragen, Inc. | MiRNA biomarkers of lung disease |
US8921333B2 (en) | 2009-10-01 | 2014-12-30 | National Cancer Center | Therapeutic agent for tumor |
EP2486929A1 (en) * | 2009-10-01 | 2012-08-15 | National Cancer Center | Therapeutic agent for tumor |
EP2486929A4 (en) * | 2009-10-01 | 2013-04-03 | Nat Cancer Ct | Therapeutic agent for tumor |
WO2011053257A3 (en) * | 2009-11-02 | 2011-08-18 | Agency For Science, Technology And Research (A*Star) | Methods for monitoring cellular states and for immortalizing mesenchymal stem cells |
US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
CN103080334B (en) * | 2010-06-04 | 2016-05-04 | 复旦大学 | For diagnosing microRNA biomarker and the method for early stage colorectal cancer and senior adenoma |
CN103080334A (en) * | 2010-06-04 | 2013-05-01 | 复旦大学 | Micro-RNA biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma |
US9682095B2 (en) | 2010-07-06 | 2017-06-20 | Interna Technologies B.V. | MiRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway |
US9006201B2 (en) | 2010-07-08 | 2015-04-14 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for diabetes |
US8946187B2 (en) | 2010-11-12 | 2015-02-03 | The Ohio State University | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
US11679157B2 (en) | 2010-11-15 | 2023-06-20 | The Ohio State University | Controlled release mucoadhesive systems |
US10758619B2 (en) | 2010-11-15 | 2020-09-01 | The Ohio State University | Controlled release mucoadhesive systems |
WO2012089630A1 (en) | 2010-12-30 | 2012-07-05 | Fondazione Istituto Firc Di Oncologia Molecolare (Ifom) | A METHOD TO IDENTIFY ASYMPTOMATIC HIGH-RISK INDIVIDUALS WITH EARLY STAGE LUNG CANCER BY MEANS OF DETECTING miRNAs IN BIOLOGIC FLUIDS |
US9441222B2 (en) | 2011-01-11 | 2016-09-13 | Interna Technologies B.V. | MiRNA for treating diseases and conditions associated with neo-angiogenesis |
US9611478B2 (en) | 2011-02-03 | 2017-04-04 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
ITMI20110173A1 (en) * | 2011-02-07 | 2012-08-08 | Fond Irccs Istituto Nazional E Dei Tumori | PROCEDURE AND EQUIPMENT TO IDENTIFY INDIVIDUALS AT RISK OF PULMONARY AND / OR TO DIAGNOSE A PULMONARY CANCER, AS WELL AS COMPOSITION AND METHOD TO REDUCE OR ELIMINATE THE RISK OF PULMONARY CANCER |
WO2012107841A3 (en) * | 2011-02-07 | 2013-01-17 | Biomirna Holdings Ltd. | Micro -rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof |
ITMI20110174A1 (en) * | 2011-02-07 | 2012-08-08 | Fond Irccs Istituto Nazional E Dei Tumori | PROCEDURE AND EQUIPMENT TO IDENTIFY INDIVIDUALS AT RISK OF PULMONARY AND / OR TO DIAGNOSE A PULMONARY CANCER, AS WELL AS COMPOSITION AND METHOD TO REDUCE OR ELIMINATE THE RISK OF PULMONARY CANCER |
US9926603B2 (en) | 2011-02-07 | 2018-03-27 | Biomirna Holdings Ltd. | Micro-RNA biomarkers and methods of using same |
US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
US9914972B2 (en) | 2011-03-28 | 2018-03-13 | Rosetta Genomics Ltd. | Methods for lung cancer classification |
EP2691545A2 (en) * | 2011-03-28 | 2014-02-05 | Rosetta Genomics Ltd | Methods for lung cancer classification |
EP2691545A4 (en) * | 2011-03-28 | 2015-04-15 | Rosetta Genomics Ltd | Methods for lung cancer classification |
EP2505663A1 (en) | 2011-03-30 | 2012-10-03 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids |
US10655184B2 (en) | 2011-09-13 | 2020-05-19 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
US9249468B2 (en) | 2011-10-14 | 2016-02-02 | The Ohio State University | Methods and materials related to ovarian cancer |
US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
US9481885B2 (en) | 2011-12-13 | 2016-11-01 | Ohio State Innovation Foundation | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
CN102559884A (en) * | 2011-12-27 | 2012-07-11 | 芮屈生物技术(上海)有限公司 | LET-7micro ribose nucleic acid (MIRNA) level in-situ hybridization detection kit for pathologic evolution early stage of various cancer, and detection method and application |
US9434995B2 (en) | 2012-01-20 | 2016-09-06 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
WO2015056195A1 (en) | 2013-10-15 | 2015-04-23 | Warszawski Uniwersytet Medyczny | Use of microrna markers for diagnosis of liver lesions |
WO2015071876A2 (en) | 2013-11-14 | 2015-05-21 | Warszawski Uniwersytet Medyczny | Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers. |
US12117462B2 (en) | 2014-06-18 | 2024-10-15 | Toray Industries, Inc. | Lung cancer detection kit or device, and detection method |
US10316318B2 (en) | 2015-06-05 | 2019-06-11 | MiRagen Therapeutics, Inc. | Oligonucleotide compositions and uses thereof |
US9994852B2 (en) | 2015-06-05 | 2018-06-12 | MiRagen Therapeutics, Inc. | Oligonucleotide compositions and uses thereof |
US9771585B2 (en) | 2015-06-05 | 2017-09-26 | MiRagen Therapeutics, Inc. | miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) |
WO2017194814A1 (en) * | 2016-05-13 | 2017-11-16 | Servicio Andaluz De Salud | Micro-rnas as biomarkers for the diagnosis of lung cancer |
WO2017217935A1 (en) * | 2016-06-14 | 2017-12-21 | Agency For Science, Technology And Research | Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma |
US11053496B2 (en) | 2016-06-14 | 2021-07-06 | Agency For Science, Technology And Research | Consequences of a defective switch in cutaneous squamous cell carcinoma |
US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
CN106755521A (en) * | 2017-02-20 | 2017-05-31 | 南京九寿堂医药科技有限公司 | Blood plasma microRNAs is used for the purposes of the diagnostic reagent for preparing patients with lung adenocarcinoma in sieving and diagnosis female group |
US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
US12043872B2 (en) | 2017-06-29 | 2024-07-23 | Toray Industries, Inc. | Kit, device, and method for detecting lung cancer |
EP3880849A4 (en) * | 2018-11-12 | 2022-08-24 | Mirxes(Hangzhou) Biotechnology Co., Ltd | A peripheral blood mirna marker for diagnosis of non-small cell lung cancer |
CN109385478A (en) * | 2018-12-20 | 2019-02-26 | 首都医科大学附属北京朝阳医院 | The genetic marker for detecting 19-GCS is preparing the application in the product for diagnosing early stage adenocarcinoma of lung prognosis |
CN109385478B (en) * | 2018-12-20 | 2021-08-03 | 首都医科大学附属北京朝阳医院 | Application of gene marker for detecting 19-GCS in preparation of product for diagnosing early lung adenocarcinoma prognosis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8377637B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P | |
JP5837909B2 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
JP5490413B2 (en) | Abnormal microRNA expression in pancreatic endocrine and acinar tumors | |
US8530159B2 (en) | MiR-29-based methods for the diagnosis and prognosis of acute myeloid leukemia (AML) | |
AU2016203583A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
AU2014203454B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
AU2013245505B2 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
AU2012238336B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
AU2016203848B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2633674 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12160034 Country of ref document: US Ref document number: 2007205234 Country of ref document: AU Ref document number: 2007717734 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008549549 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007205234 Country of ref document: AU Date of ref document: 20070103 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780006750.8 Country of ref document: CN |